

SWH 01177

SWFT Drug Formulary

Version	1.0
Job Title of Responsible Manager	Head of Pharmacy
Replacing Document	None
Ratifying 'Body'	Drug and Therapeutic Committee
Date Ratified	December 2014
Date for Review	December 2017
Relevant Standards:	Health and Social Care Act2008 Regulation 13

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
1.1	Dyspepsia and Gastro-oesophageal Reflux Disease			
1.1.1	Antacids and Simeticone			NICE Clinical Guideline CG17: Dyspepsia; Managing dyspepsia in adults in primary care
			Infacol Drops	
			Peptac Oral Suspension	
			Gaviscon Infant Sachets	
1.1.2	Compound Alginates and Proprietary Indigestion Preparations			
1.2	Antispasmodics and other drugs altering gut motility			
		Antimuscarinics		
			Hyoscine-N-butylbromide Tablets 10mg	NICE CG61: Irritable Bowel Syndrome
			Hyoscine-N-butylbromide 20mg in 1ml Injection	
			Alverine Citrate Capsules	
			Mebeverine Tablets	
			Mebeverine 50mg in 5ml Liquid R (Restricted due to high cost)	
			Peppermint Oil Capsules MR EC (Colpermin)	
			Peppermint Oil Capsules EC (Mintec)	
			Peppermint Water	
		Motility stimulants		
			Metoclopramide Tablets, Oral Solution, Injection	
			Domperidone Tablets	
				NICE CG99: Constipation in children and young people NICE CG49: Faecal incontinence
			Erythromycin Tablets R (Restrict to gastroparesis)	
1.3	Antisecretory Drugs and Mucosal Protectants			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
1.3.1	H2 Receptor Antagonists			
		1st line	Ranitidine Tablets	NICE Clinical Guideline CG17: Dyspepsia; Managing dyspepsia in adults in primary care
			Ranitidine Oral Solution 75mg/5mL sugar free, Injection (Restrict to patients with swallowing difficulties or paediatrics).	
			Cimetidine R (Restrict if alternatives not suitable).	
1.3.3	Chelates and Complexes			
			Tripotassium Dicitratobismuthate Tablets (De Nol) R (Restrict if alternatives not suitable)	
			Sucralfate Tablets 1g R (Restrict if alternatives not suitable)	
1.3.4	Prostaglandin Analogues			
1.3.5	Proton Pump Inhibitors			NICE CG 141: Acute upper GI bleeding NICE CG 17: Dyspepsia SIGN clinical guideline 105 - management of acute upper and lower gastrointestinal bleeding SWFT H Pylori eradication (See SWFT Antibiotic Policy for details)
		1st line	Lansoprazole Capsules	MHRA on Clopidogrel and proton pump inhibitors interaction (2010)
		2nd line	Omeprazole Capsules (40mg capsules are non formulary due to high costs)	MHRA Proton pump inhibitors in long-term use: reports of hypomagnesaemia April 12 MHRA Proton pump inhibitors in long-term use: reports of hypomagnesaemia April 12
		3rd line	Esomeprazole 40mg Capsules, Tablets	
		3rd line	Pantoprazole Tablets	
		3rd line	Rabeprazole Tablets	
		1st line (For swallowing difficulties)	Lansoprazole Orodispersible Tablets R (Restrict to patients with swallowing difficulties e.g. NG tubes etc)	
		2nd line (For swallowing difficulties)	Omeprazole Dispersible Tablets R (Restrict to patients with swallowing difficulties e.g. NG tubes etc)	
			Omeprazole IV Infusion 40mg R (when oral prep not appropriate)	
1.4	Acute Diarrhoea			NICE CG84: Diarrhoea and vomiting in children under 5yrs

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
1.4.2	Antimotility Drugs			
			Co-phenotrope Tablets	
			Loperamide Capsules, Syrup, Tablets	
1.5	Chronic bowel disorders			
1.5.1	Aminosalicylates		Prescribe aminosalicylates by brand name	NICE CG 61: Irritable Bowel Syndrome NICE CG 49: Faecal incontinence NICE CG152: Crohn's disease NICE CG166: Ulcerative Colitis
		1st line	Octasa (Mesalazine) Tablets 400mg	
			Asacol (Mesalazine) Foam Enema 1g/metered application	
			Asacol (Mesalazine) Suppositories	
			Asacol MR (Mesalazine) Tablets	
			Pentasa (Mesalazine) Tablets	
			Pentasa (Mesalazine) Suppositories	
			Pentasa (Mesalazine) Retention Enema 1G in 100ml	
			Pentasa (Mesalazine) Sachets	
			Salofalk (Mesalazine) 1g Rectal Foam	
			Salofalk (Mesalazine) 2g Enema	
		2nd line	Olsalazine (Dipentum) Capsules, Tablets	
		2nd line	Balsalazide (Colazide) Capsules	
		3rd line	Sulfasalazine Tablets, Tablets EN, Suppositories, Suspension	
1.5.2	Corticosteroids			
			Budesonide Capsules E/C 3mg (Budenofalk) 3mg,	
			Budesonide (Entocort) 3mg MR Capsules R	
			Hydrocortisone IV see BNF Section 6.3.2	
			Hydrocortisone Foam 10% Enema (Colifoam)	
			Prednisolone Rectal Foam Enema 20mg (Predfoam)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Prednisolone 20mg Retention Enema (Predsol)	
			Prednisolone 5mg Suppositories	
			Prednisolone Oral Preparations see BNF Section 6.3.2	
1.5.3	Immunomodulators			
			Azathioprine Tablets SC (Restrict to gastrospecialists in IBD clinics)	
			6-Mercaptopurine Tablets 50mg SC (Restrict to gastrospecialists in IBD clinics).	
			Methotrexate Tablets SC (Restrict to gastrospecialists in IBD clinics)	NPSA Safety Alert 13: Oral methotrexate. Improving compliance with oral methotrexate guidelines (June 2006)
			Methotrexate PFS SC (Restrict to gastrospecialists in IBD clinics)	
			Infliximab SO (Restrict to gastrospecialists in IBD clinics. To be used in Crohn's and Acute Ulcerative Colitis. Evidence of compliance with agreed criteria required)	NICE TA 187: Crohn's disease- Infliximab and Adalimumab NICE TA 140: Ulcerative colitis (subacute manifestations) Infliximab NICE TA 163: Ulcerative colitis (acute manifestations) Infliximab
			Adalimumab SO (Restrict to gastrospecialists in IBD clinics. To be used in Crohn's. Evidence of compliance with agreed criteria required)	NICE TA 187: Crohn's disease- Infliximab and Adalimumab
1.6	Laxatives			Constipation management - MeReC Bulletin (Jan 2011 NICE CG61: Irritable Bowel Syndrome) NICE CG99: Constipation in children and young people
1.6.1	Bulk-forming Laxatives			
			Ispaghula Husk Granules	
1.6.2	Stimulant Laxatives			
			Bisacodyl Suppositories	
			Bisacodyl EC 5mg Tablets	
			Co-danthramer 25/200 Capsules, Suspension R (For use in Terminally ill)	
			Co-danthramer Strong 37.5/500 Capsules, Suspension R (For use in Terminally ill)	
			Co-danthrusate 50/60 Capsules, Suspension R (for use in Terminally ill)	
			Docusate sodium 100mg Capsules	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Docusate sodium 50mg in 5ml Oral Solution (Adult)	
			Docusate sodium 12.5mg in 5ml Oral Solution (Paediatric)	
			Glycerol Suppositories 1G, 2G (Paediatrics) 4g	
			Senna Tablets, Syrup, Granules	
			Sodium Picosulphate Liquid	
			Sodium Picosulphate Oral Powder	
1.6.3	Faecal Softeners			
			Arachis Oil Enema	
			Liquid Paraffin & Magnesium Hydroxide Emulsion	
1.6.4	Osmotic Laxatives			
			Lactulose Liquid	
			Macrogol 3350 Sachets Adult	
			Macrogol 3350 Paediatric Sachets	
			Magnesium Hydroxide Mixture	
			Fleet Ready to Use Enema	
			Phosphate Enema Standard and Long Tube	
			Sodium Citrate Micro -enema	
1.6.5	Preparations			
			Klean-Prep Oral Powder R	
1.6.7	5HT4 Receptor Agonists and guanylate cyclase-C receptor agonists			
			Prucalopride Tablets SA R (Chronic constipation in women when other laxatives fail to provide an adequate response)	NICE TA211: Constipation (women) - prucalopride
1.7	Local Preparations for anal and rectal disorders			
1.7.1	Soothing haemorrhoidal preparations			
			Anusol Ointment, Suppositories	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
1.7.2	Compound haemorrhoidal preparations			
			Anugesic HC Suppositories	
			Anusol HC Ointment, Suppositories	
			Proctofoam HC Foam	
			Proctosedyl Ointment. Suppositories	
			Xyloproct Ointment	
1.7.3	Rectal Sclerosants			
			Oily phenol injection BP- R	
1.7.4	Management of anal fissures			
			Glyceryl Trinitrate 0.4% Rectal Ointment	
1.8	Stoma care			
1.9	Drugs affecting intestinal secretions			
1.9.1	Drugs affecting biliary composition and flow			
			Ursodeoxycholic Acid Tablets 150mg, Capsules 250mg, Suspension 250mg/5ml SA	
1.9.2	Bile acid secretions			
			Colestyramine low sugar 4g Sachets	
1.9.3	Aprotinin			
1.9.4	Pancreatin			
			Creon Capsules 10000, 25000, 40000 SA	
<p><u>Discouraged List</u> Kaolin products including Kaolin mixture and Kaolin and Morphine, Brand names = De Witts® Antacid powder, Entrocalm® tabs, Fullers earth crm, J. Collis Brownes® tabs, Kao-C® Junior susp, Kaodene® susp, Moorlands® tabs, Opazimes® tabs. Rationale = BNF: absorbents such as Kaolin not recommended for acute diarrhoea. Effective agents with lesser addiction potential are available. Advice = Consider re-hydration sachets/loperamide as appropriate for short term management of symptoms. Consider the cause of the episode of diarrhoea and manage appropriately.</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
2.1	Positive Inotropic Drugs			
2.1.1	Cardiac Glycosides			
				NICE CG 180: The Management of Atrial Fibrillation, June 2014. NICE CG108: Management of chronic heart failure in adults in primary and secondary care, August 2010. SIGN Guideline 94: Cardiac arrhythmias in coronary heart disease, February 2007. SIGN Guideline 95: Management of chronic heart failure, February 2007.
			Digoxin. Tablets, Elixir, 500micrograms/2ml Injection	
	Digoxin-specific antibody		Digifab Injection R (Restrict to Cardiologist. Stock shared with UHCW and GEH)	
2.1.2	Phosphodiesterase Type-3 Inhibitors			
2.2	Diuretics			
2.2.1	Thiazides and Related Diuretics			NICE CG127: Hypertension; Clinical management of primary hypertension in adults. NICE CG107: Hypertension in pregnancy Management of hypertensive disorder in pregnancy. C&W APC Clinical Guideline CG006: (Rev): Hypertension Management Guidelines, January 2013.
		1st line	Indapamide 2.5mg standard release Tablets	
		1st line	Chlortalidone Tablets	
		2nd line	Bendroflumethiazide Tablets	
			Metolazone Tablets R (Unlicensed)	
			Chlorothiazide 250mg/5ml Suspension R (Paediatrics) (Unlicensed)	
2.2.2	Loop Diuretics			
			Furosemide Tablets, Liquid, Injection	Single IV doses of 40mg or 80mg can be given as a bolus. Larger doses must be infused at a max rate of 4mg/min.
			Bumetanide Injection, Liquid, Tablets	
			Torsemide Tablets R	
2.2.3	Potassium-Sparing Diuretics and Aldosterone Antagonists			SIGN Guideline 95: Management of chronic heart failure, February 2007. NICE CG108: Management of chronic heart failure in adults in primary and secondary care, August 2010.

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Amiloride Liquid, Tablets	
	Aldosterone Antagonists			
			Eplerenone Tablets SI	
			Spirolactone Tablets, Suspension (Unlicensed)	
2.2.4	Potassium-Sparing Diuretics with other Diuretics			
			Co-amilofruse (amiloride/furosemide) Tablets	
			Co-amilozide (amiloride/hydrochlorothiazide) Tablets	
2.2.5	Osmotic Diuretics			
			Mannitol Infusion R (Specialist)	
2.3	Anti-Arrhythmic Drugs			
2.3.2	Drugs for Arrhythmias			NICE CG36: The Management of Atrial Fibrillation June 2006.
		Supraventricular arrhythmias		
			Adenosine Injection 6mg/2ml	
			Dronedarone Tablets SC	NICE TA197: Atrial fibrillation - Dronedarone August 2010. ESCA - Dronedarone - Shared Care Agreement: for treatment of non-permanent atrial fibrillation.
		Supraventricular and ventricular arrhythmias		
			Amiodarone 150mg/3ml Injection, Tablets SA	
			Disopyramide Capsules/ MR Tablets SA	
			Flecainide Injection, Tablets, Syrup SA	
			Propafenone Tablets	
		Ventricular arrhythmias		
			Lidocaine Injection 1.0%, 5ml, 10ml	
			Lidocaine Injection 2.0%, 2ml, 5ml	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
2.4	Beta-Adrenoceptor Blocking Drugs			
				NICE Clinical Guideline CG108: Chronic heart failure: Management of chronic heart failure in adults in primary and secondary care. NICE CG 126: Stable Angina NICE CG 127: Hypertension NICE CG 36: Atrial fibrillation NICE CG 48: MI secondary prevention
		Heart Failure		
		1st line	Bisoprolol Tablets SA (HF, HT, angina)	
		1st line	Nebivolol Tablets (HF, HT)	
		1st line	Carvedilol Tablets SA (HF, HT, angina)	
		Beta Blockers for other indications		
		1st line	Bisoprolol Tablets	
		1st line	Atenolol Tablets, Injection, Syrup	
			Propranolol IV Infusion, Tablets, Capsules, Syrup	
			Labetolol 100mg/20ml Injection, Tablets	
			Esmolol Injection / Infusion (Hospital only)	
			Metoprolol 5mg/5ml Injection, Tablets	
			Sotalol Tablets	
			Co-tenidone	
2.5	Hypertension and Heart Failure			
2.5.1	Vasodilator and Antihypertensive Drugs			
			Hydralazine Injection, Tablets	
			Iloprost R (To Specialist)	
2.5.2	Centrally Acting Antihypertensive Drugs			
			Clonidine Injection, Tablets	
			Methyldopa Tablets	
			Moxonidine Tablets	
2.5.4	Alpha-Adrenoceptor Blocking Drugs			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Doxazosin Tablets	
			Indoramin Tablets	
			Phentolamine 10mg/ml R	
2.5.5	Drugs affecting the Renin Angiotensin System			
2.5.5.1	Angiotensin Converting Enzyme Inhibitors			C&W APC Clinical Guideline CG006(Rev): Hypertension Management Guidelines C&W APC ACE ARB - Brief Prescribing Guide, September 2011. NICE CG 108: Chronic heart failure NICE CG 127: Hypertension (algorithm page 13) NICE CG 48: MI secondary prevention NICE CG 87: Type 2 Diabetes - newer agents (a partial update of CG66) ACEi & A2A MeReC review (2010) MHRA. Combination use of Medicines from different classes of RAS blocking agents. Vol 7 Issue 11, June 2014.
		1st line	Ramipril Capsules, Tablets	
		1st line	Lisinopril Tablets	
		1st line	Perindopril erbumine Tablets	
		1st line	Enalapril Tablets	
			Lisinopril/hydrochlorothiazide Tablets	
2.5.5.2	Angiotensin-II Receptor Antagonists			
		1st line	Losartan Tablets	
		1st line	Candesartan Tablets	
			Valsartan Capsules	
			Irbesartan Tablets	
			Olmesartan Tablets	
			Telmisartan Tablets	
2.5.5.3	Renin inhibitors			
			Aliskiren Tablets R (Specialist)	C&W APC Aliskiren Drug positioning statement
2.6	Nitrates, Calcium Channel Blockers and Potassium Channel Activators			
2.6.1	Nitrates			
		short acting	Glyceryl Trinitrate Spray, Sublingual Tablets, Injection 10mg/ml	NICE Clinical Guideline CG126: Management of stable angina
			Isosorbide Mononitrate standard release Tablets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		long acting	Isosorbide Mononitrate MR Tablets	
			Isosorbide Dinitrate Injection 25mg/50ml, Tablets	
2.6.2	Calcium Channel Blockers			NICE CG 36: Atrial fibrillation
				C&W APC Clinical Guideline CG006(Rev): Hypertension Management Guidelines NICE Clinical Guideline CG127: Hypertension; Clinical management of primary hypertension in adults NICE Clinical Guideline CG126: Management of stable angina
		Hypertension (HT)		
			Amlodipine (HT)	
			Lacidipine Tablets (HT)	
			Lercanidipine Tablets (HT)	
		Other indications		
			Amlodipine Tablets (HT, angina)	
			Diltiazem MR/XL Tablets, Capsules (HT, angina)	
			Nifedipine XL Tablets, Capsules (HT, angina)	
			Felodipine Tablets (HT, angina)	
			Nicardipine Capsules (HT, angina)	
			Verapamil Tablets and SR, Capsules MR, Verapamil 5mg/2ml Injection (supraventricular arrhythmias, angina, HT, cluster headaches)	
			Nimodipine Injection and Tablets R (SAH)	
2.6.3	Other Antianginal Drugs			NICE TA267: Chronic heart failure NICE Clinical Guideline CG126: Management of stable angina MHRA Drug safety update. Ivabradine. Vol 7 Issue 11, June 14.
			Ivabradine Tablets SA	
			Nicorandil Tablets	MHRA advice on risk of ulceration
			Ranolazine MR Tablets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
2.6.4	Peripheral Vasodilators and Related Drugs			NICE CG 147: Lower limb peripheral arterial disease: guidance NICE TA223: Peripheral arterial disease
			Naftidrofuryl Oxalate Capsules	
2.7	Sympathomimetics			
2.7.1	Inotropic Sympathomimetics			
			Dopexamine 50mg/5ml Injection R (To ITU and CCU)	
			Dobutamine Injection 250mg/20ml R (To ITU and CCU)	
			Dopamine Injection 200mg/5ml R (To ITU and CCU)	
			Isoprenaline 200mcg/10ml min-I-jet - R (To ITU and CCU)	
2.7.2	Vasodilator Sympathomimetics			
			Ephedrine Injection 30mg/ml R (To ITU)	
			Noradrenaline (Norepinephrine) Injection 4mg/4ml R (To ITU)	
			Metaraminol Injection 10mg/ml R (To ITU) (Unlicensed)	
			Phenylephrine Injection 10mg/ml R (To ITU)	
2.7.3	Cardiopulmonary Resuscitation			
			Adrenaline (Epinephrine) Injection 1:10,000/ml Syringe	
2.8	Anticoagulants and Protamine			
2.8.1	Parental Anticoagulants			
	Heparin			NICE CG 92: Venous thromboembolism: reducing the risk. NICE guidance CG94: Unstable angina and NSTEMI, March 2010. NPSA alert: Risks with Intravenous Heparin Flush Solutions. NICE CG 144: Venous thromboembolic diseases. British Haematology Society guidelines on the use and monitoring of heparin, 2006.
			Heparin Na 25,000 units/ml Injection	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Heparin 1000 units Injection	
			Heparin Na 1000iu + Na Cl 0.9%	
			Heparin Na Flushing Solution 50 units/5ml Injection	
			Heparin 1000units + Sodium chloride 0.9% IV Infusion	
	Heparin flushes		Heparin flush Injection 50 units/5ml	
	Low molecular weight heparins			C&W APC drug positioning statement - LMWHs in Pregnancy (must be SI), August 2011. NPSA alert: Reducing treatment errors with LMWH UKMI Q&A: Are low molecular weight heparins preferred to unfractionated heparin in people with renal impairment for treatment indications? UKMI Q&A: Should prophylactic doses of low molecular weight heparins be used in patients with renal impairment?
			Enoxaparin 10, 000 units/ml Injection (100mg/ml) SI R (ACS)	
			Tinzaparin 20,000 units/ml Injection SA (Treatment)	
			Tinzaparin 10, 000 units/ml Injection SA (Prophylaxis) (Off label in medical patients)	
	Heparinoids			
			Danaparoid Sodium Injection 1250units/ml R (Specialist HIT)	Hospital guidelines are being written.
			Epoprostenol Inf 500mcg SO	
	Fondaparinux		Fondaparinux sodium Injection SO R (Specialist HIT)	Fondaparinux indication: for the treatment of unstable angina or non ST-elevation myocardial infarction.
2.8.2	Oral Anticoagulants			
		Coumarins and Phenindione		Anticoagulation - Safety Alert Notice:NPSA Alert 18.
		1st line	Warfarin Tablets	NHS Safety: Preventing fatalities from medication loading doses.
		2nd line	Phenindione Tablets R	
		2nd line	Acenocoumarol Tablets R	
				NICE CG 36: Atrial Fibrillation NICE CG 48: MI secondary prevention.

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Dabigatran Tablets SA (Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation)	NICE TA249: Atrial fibrillation - dabigatran etexilate.
			Dabigatran Tablets SO (Prevention of VTE following elective hip or knee replacement surgery)	NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults.
			Rivaroxaban Tablets SA (Prevention of stroke and systemic embolism in non-valvular atrial fibrillation,)	NICE TA256: Atrial fibrillation (stroke prevention) - rivaroxaban. NICE TA261: Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban. NICE TA287: Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban. NICE TA170: Rivaroxaban for the prevention of venous thromboembolism Apr 2009.
			Rivaroxaban Tablets SA (Treatment of DVT and PE. Prevention of recurrent DVT or PE)	
			Rivaroxaban Tablets SO (For prophylaxis of venous thromboembolism following knee or hip surgery)	
		(2nd line NOAC for prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation)	Apixaban Tablets SA (Prevention of VTE following elective hip or knee replacement surgery) R- (2nd line NOAC for prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation)	NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban used in stroke in AF. NICE TA245: Venous thromboembolism - apixaban (hip and knee surgery)
2.8.3	Protamine Sulphate		Protamine Sulphate 50mg/5ml Injection	
2.9	Antiplatelet Drugs			NICE CG 36: Atrial Fibrillation NICE CG 48: MI secondary prevention NICE CG96: Chest pain of recent onset NICE CG126: Stable Angina NICE CG 94: Unstable angina and NSTEMI NICE CG130: Hyperglycaemia in ACS NICE CG68: Stroke and TIA NICE TA152: Drug – eluting stents for the treatment of coronary artery disease NICE TA 210: Vascular disease - clopidogrel and dipyridamole (Review of TA90) NICE TA236: Acute Coronary Syndromes -ticagrelor C&W APC Clopidogrel Generic - Urgent bulletin Dec 09

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Aspirin 75mg Dispersible Tablets	
			Clopidogrel Tablets	
			Dipyridamole MR Capsules	
			Ticagrelor Tablets SI - R (STEMI Pts Only)	
			Tirofiban IV Infusion 12.5mg in 250mls R (Cardiology Only)	
2.10	Stable Angina, Acute Coronary Syndromes and Fibrinolysis			
2.10.1	blank			
2.10.2	Fibrinolytic Drugs			NICE CG68: Stroke NICE TA52: Myocardial infarction - thrombolysis NICE CG 48: MI - secondary prevention
			Alteplase Injection R (For PE only. Refer to UHCW for stroke thrombolysis)	NICE TA264: Alteplase for treating acute ischaemic stroke
			Urokinase Injection 25,000 unit injection R (Unblocking lines)	
2.11	Anti-Fibrinolytics			
			Tranexamic Acid, Tablets, Injection	NICE CG 44: Heavy Menstrual Bleeding
2.12	Lipid-Regulating Drugs			
	Statins			
				C&W APC CG002(Rev): Lipid Modification Guidelines, November 2012 NICE CG67: Lipid modification; Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE CG 71: Familial Hyper-cholesterolaemia. NICE CG 73: Chronic Kidney disease. NICE CG 87: Type 2 Diabetes - newer agents (a partial update of CG66) NICE TA94: Cardiovascular disease - statins.
				MHRA Advice: Simvastatin: updated advice on drug interactions - updated contraindications. MHRA Statins and benefits May 2014. Vol 7 issue 10, May 2014.
		1st line	Atorvastatin Tablets	
		1st line	Simvastatin Tablets	
		1st line	Pravastatin Tablets	
			Rosuvastatin Tablets	
			Fluvastatin Tablets	
	Bile acid sequestrants			
			Colestyramine Sachets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
	Ezetimibe			NICE TA 132: Ezetimibe
			Ezetimibe Tablets	
	Fibrates			
			Bezafibrate Tablets and MR tablets	
			Ciprofibrate 100mg Tablets	
			Fenofibrate Tablets	
<p><u>Not recommended by APC.</u> Cilostazol for Intermittent claudication in patients without rest pain and no peripheral tissue necrosis (NICE TA223), Pentoxifylline for Peripheral vascular disease (NICE TA223) , Inositol nicotinate - Peripheral vascular disease (NICE TA223). Azilsartan. <u>Discouraged List</u></p> <p>Simvastatin with Ezetimibe (Inegy®), Trandolapril with Verapamil (Tarka®), Amlodipine with Valsartan (Exforge®), Modified release Doxazosin preparations, Perindopril arginine and Perindopril arginine with Indapamide (Coversyl® Arginine, Coversyl® Arginine Plus), Cilostazol (Pletal®), Inositol (Hexopal®), Pentoxifylline (Trental®, Neotren MR®, Pentofin®)</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
				British Guideline on the Management of Asthma (SIGN/BTS) C&W APC Asthma - Guidelines:prescribing for adults and adolescents NICE TA 38 Inhaler devices for children 5-15 with chronic asthma. Mar 2002 NICE TA10: Asthma (children under 5) - inhaler devices Aug 2000
				NICE CG101: Chronic obstructive pulmonary disease; Management of chronic obstructive pulmonary disease in adults in primary and secondary care COPD MeRec Bulletin June 2006 C&W APC COPD - Guidelines:COPD prescribing COPD MeRec Bulletin June 2006
				Bronchiectasis (non-CF) BTS guideline 2010
3.1	Bronchodilators			
3.1.1	Adrenoceptor Agonists			
			Ephedrine 30mg in 1mL Injection	
3.1.1.1	Selective Beta agonists			
		Short Acting Beta Agonists (SABA)		
		1st line	Salbutamol 100mcg MDI CFC free	
		1st line	Salbutamol MDI (Ventolin) R (Brand to be used in paediatrics only)	
		1st line	Salbutamol 100mcg Easyhaler DPI	
		2nd line	Salamol: Salbutamol Easibreathe MDI	
			Salbutamol 200mcg Accuhaler DPI	
			Airomir Autohaler MDI	
			Pulvinal Salbutamol DPI	
			Asmasal Clickhaler DPI	
			Salbutamol Nebules 2.5mg, 5mg	
		2nd line	Dry Powder: Terbutaline 500mcg Turbohaler DPI	
			Terbutaline 5mg in 2ml Respules	
		Long Acting Beta Agonists (LABA)		
		1st line	Formoterol 12mcg Easyhaler® DPI	
		2nd line	Formoterol 6mcg, 12mcg Turbohaler DPI	
		2nd line	Atimos Modulite: Formoterol 12 mcg MDI	
		2nd line	Salmeterol 25mcg Evohaler® MDI,50mcg Accuhaler DPI	

		3rd line	Indacaterol 150mcg, 300mcg DPI R	
			Salbutamol 500mcg/ml, 5mg/5ml Injection	
3.1.1.2	Other Adrenoreceptor Agonists			
3.1.2	Antimuscarinic Bronchodilators			
		SAMAs		
			Ipratropium 20mcg Aerosol Inhaler	
			Ipratropium 250mcg , 500mcg Nebules	
		LAMAs		
		1st line	Tiotropium 18mcg Inhaler DPI Refill and Combopak	
		1st line	Glycopyrronium Inhaler 55mcg DPI	
		2nd line	Acclidinium Inhaler 322mcg DPI	
3.1.3	Theophylline		(Prescribe by brand)	
			Nuelin Tablets	
			Slo-phyllin SR Capsules	
			Uniphyllin Tablets	
			Aminophylline MR Tablets	
			Aminophylline 25mg/ml Injection	
3.1.4	Compound Bronchodilators preparations			
			Ipratropium and Salbutamol Nebules (Generic brand only)	
3.1.5	Peak flow meters, inhaler devices and nebulisers			
			Peak flow - Mini Wright	
			Aerochanber	
			Haleraid	
			Volumatic	
3.2	Corticosteroids			NICE TA128 - Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over NICE TA 131: Asthma (in children) - corticosteroids NICE TA 138: Asthma (in adults) - corticosteroids
		Inhaled corticosteroids		
		Beclomethasone Inhaler		MHRA advice - Prescribe beclomethasone inhalers by brand name.

		1st line	Clenil Modulite MDI	
		1st line	Beclometasone Easyhaler DPI	
		2nd line	Qvar Easi-Breathe MDI	
		2nd line	Budesonide Easyhaler DPI	
		2nd line	Budesonide Turbohaler DPI	
			Qvar Inhaler MDI (NB Qvar brand is more potent for equivalent strength)	
			Qvar Autohaler MDI	
			Ciclesonide 80mcg, 160mcg R (Restrict to respiratory specialists and for patients admitted on this medication)	
			Fluticasone MDI (Evohaler), DPI and (Accuhaler)	
			Budesonide Nebules	
		Combination products		
		1st line	Fostair Beclometasone/ Formoterol (100/6) MDI	
		1st line	Flutiform Fluticasone/ Formoterol MDI	
		1st line	Symbicort Turbohaler Budesonide/Formoterol DPI	
		1st line	Seretide Accuhaler[®] DPI Fluticasone/Salmeterol (50mcg)	
		2nd line	Seretide Evohaler[®] MDI Fluticasone/Salmeterol (25mcg)	
3.3	Cromoglycate and related therapy, Leukotriene Receptor Antagonist and Phosphodiesterase type-4 Inhibitors			
3.3.1	Cromoglycate and related therapy			
			Sodium Cromoglicate MDI R	
			Nedocromil Sodium MDI R	
3.3.2	Leukotriene Receptor Antagonist			
			Montelukast Tablets, ,Chewable,Granules	

3.3.3	Phosphodiesterase type-4 Inhibitors			
3.4	Antihistamine, hyposensitisation and allergic emergencies			
3.4.1	Antihistamines			
		1st line	Loratadine Tablets, Oral Solution	
		1st line	Cetirizine Tablets, Oral Solution SF	
			Acrivastine 8mg Capsules	
			Chlorphenamine Tablets, Syrup SF, Injection	
			Hydroxyzine Tablet, Syrup	
			Alimemazine Tablets, Syrup	
			Promethazine Tablets, Injection, Syrup	
			Levocetirizine Tablets	
			Desloratadine 5mg Tablets R (Specialists only . Only to be if all other antihistamine options have been tried).	
			Fexofenadine Tablets	
3.4.3	Allergic Emergencies			NICE CG134 Anaphylaxis Resuscitation Council UK Guidance 2008: Anaphylaxis algorithm
			Adrenaline (Epinephrine) Injection, Auto Injector	
			Adrenaline 1mL (Epinephrine) 1 in 1000 Injection	
			C1 Esterase Inhibitor. PBR exclusion (Unlicensed)	
3.5	Respiratory Stimulants and Pulmonary Surfactants			
3.5.1	Respiratory Stimulants			
			Doxapram Infusion R (Specialist)	
			Caffeine Citrate Injection 10mg/ml, Suspension R (For paediatrics)	
			Carbon Dioxide 5% and 95% Oxygen	
3.5.2	Pulmonary Surfactants			
			Poractant Alfa Suspension	
3.6	Oxygen			Oxygen safety in hospitals Rapid Response Report September 2009 Emergency Oxygen Use in Adult Patients BTS 2008, updated 2010

3.7	Mucolytics			
			Carbocisteine Capsules, Liquid	
			Dornase alpha Inhalation SA	
3.8	Aromatic Inhalations			
3.9	Cough preparations			
3.9.1	Cough Suppressants			
			Codeine Linctus	MHRA. Codeine: restricted use as analgesic in children and adolescents after European safety review July 2013
3.9.2	Demulcent and Expectorant Cough Preparations			
			Simple Linctus	
3.10	Systemic nasal Decongestants			
3.11	Antifibrotics			
<p><u>Discouraged List</u> Roflumilast, Desloratadine (No evidence of any advantage over loratadine), N-acetyl cysteine (Not recommended for the unlicensed indication of idiopathic pulmonary fibrosis), N-Acetylcysteine is available for purchase.</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
4.1	Hypnotics and Anxiolytics			
4.1.1	Hypnotics			NICE TA77: Zaleplon, zolpidem, zopiclone for short-term management of insomnia April 2004
		1st line	Zopiclone 3.75mg/5ml Liquid and Tablets	
		2nd line	Zolpidem 5mg, 10mg Tablets	
		2nd line	Temazepam 10mg Tablets CD	
		2nd line	Temazepam 10mg/5ml Liquid CD	
		2nd line (in elderly)	Clomethiazole 192mg Capsules R (Elderly)	
			Loprazolam 1mg Tablet R (Specialist only or patients admitted on the drug)	
			Nitrazepam 5mg Tablets R (To be avoided. Only use if patient admitted on drug)	
			Nitrazepam 2.5mg in 5ml Suspension R (To be avoided. Only use if patient admitted on drug)	
		Melatonin		APC drug positioning statement for melatonin, November 2011. Melatonin - Recommended Products List July 2011. ESCA Melatonin November 2011.
			Melatonin 2mg MR Tablets (Circadin) SC	
			Melatonin Liquid 1mg/ml SC (Specialist) (Unlicensed)	
4.1.2	Anxiolytics			NICE CG 113: GAD and panic disorder (with or without agoraphobia) in adults.
		1st line	Diazepam Tablets, Oral Solution 2mg/5ml, Injection Emulsion, Injection, Rectal Tubes 2.5mg, 5mg, 10mg	
		1st line	Lorazepam Tablets, Injection 4mg/ml	
		2nd line	Buspirone Tablets R (Longer term)	
		2nd line	Oxazepam Tablets (Short term only)	
			Chlordiazepoxide Capsules, Tablets	
4.1.3	Barbiturates			
4.2	Drugs used in psychoses and related disorders			
4.2.1	Antipsychotic drugs			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
	Typical Oral antipsychotics			NICE TA213: Schizophrenia MHRA drug safety update Volume 4, Issue 9, April 2011. C&W APC Guidelines: Antipsychotic prescribing June 2012. C&W APC Antipsychotic - Prescribing Checklist: use in dementia. C&W APC Antipsychotic - Resource Pack: use in dementia September 2010. C&W APC Antipsychotic - Treatment Pathway: for withdrawal of antipsychotic in dementia September 2010. C&W APC: Reduction of Inappropriate Use of Antipsychotic Medication in people with Dementia April 2010.
		1st line	Haloperidol SA Tablets, Capsules, Injection 5mg/ml, Oral Liquid	
			Chlorpromazine Tablets, Liquid	
			Prochlorperazine Tablets, Syrup, Injection (IM route only).	
			Levomepromazine Tablets, Injection	
	Atypical oral antipsychotics			NICE TA213: Schizophrenia - Aripiprazole: quick reference guide 26 January 2011 NICE TA292: Bipolar disorder, children MHRA advice: Atypical antipsychotics: monitoring NICE CG 82: Schizophrenia (Update) C&W APC Cost Effective Use of Quetiapine Oct 13.
		1st line	Olanzapine Tablets and Orodispersible Tablets SA	
		1st line	Quetiapine Tablets and XL Tablets SA	
		1st line	Risperidone Tablets, Orodispersible Tablets, Liquid SA	
		2nd line	Amisulpiride Tablets, Liquid SA	
		2nd line	Aripiprazole Tablets, Orodispersible Tablets, Liquid SA	
			Aripiprazole Injection SI	
4.2.2	Antipsychotic depot injections			
		1st line	Flupentixol Deconate Injection SI	
		1st line	Haloperidol Deconate Injection SI	
4.2.3	Mood stabilisers - Drugs used for mania and hypomania			NPSA alert: Safer Lithium Therapy NICE CG 38: Bipolar disorder C&W APC drug positioning statement for asenapine. ESCA Lithium September 2010
		1st line	Priadel (Lithium Carbonate Tablets, Oral Liquid) SC (Lithium must be prescribed by BRAND).	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		1st line	Depakote Tablets (Valproic Acid) SA	
		2nd line	Camcolit (Lithium Carbonate Tablets) SC (Lithium must be prescribed by BRAND).	
		2nd line	Carbamazepine Tablets SA	
4.3	Antidepressant drugs			
4.3.1	Tricyclic and related antidepressant drugs			NICE CG26: Post-traumatic stress disorder (PTSD). NICE CG28: Depression in children and young people. NICE CG53: Chronic fatigue syndrome / Myalgic encephalomyelitis. NICE Clinical Guideline CG90: Depression: The management and treatment of depression in adults (Updated edition). NICE CG91: Depression with a chronic physical health problem. NICE CG 113: Generalised anxiety disorder and panic disorder in adults NICE CG 31: Obsessive Compulsive Disorder. NICE CG 9: Eating disorders C&W APC Antidepressant Guidelines: antidepressant prescribing June 2012.
		1st line	Amitriptyline Tablets, Liquid	
		1st line	Clomipramine Capsules	
		1st line	Lofepamine 70mg Tablets	
		1st line	Trazodone Capsules, Tablets, Oral Liquid	
		2nd line	Imipramine Tablets	
			Trimipramine Tablets, Capsules	
			Dosulepin Capsules, Tablets (To be avoided. Only use if patient admitted on drug)	
4.3.3	Selective serotonin re-uptake inhibitors			MHRA advice: Citalopram
		1st line	Citalopram Tablets, Liquid	
		1st line	Fluoxetine 20mg Capsules, Oral Liquid (Avoid 60mg due to expense. Use 3 x 20mg)	
		1st line	Sertraline Tablets	
			Paroxetine Tablets, Suspension	
			Escitalopram Tablets, Oral Drops R (Specialist indications)	
4.3.4	Other antidepressant drugs			
		1st line	Mirtazapine Tablets, Orodispersible Tablets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		1st line	Venlafaxine (standard release) Tablets (Specialist to initiate if daily doses are above 300mg).	C&W APC Cost Effective Use of Venlafaxine May 2012.
		2nd line	Venlafaxine XL Tablets, MR Capsules (Specialist to initiate if daily doses are above 300mg)	
		2nd line	Duloxetine Capsules	
			Flupentixol Tablets	
4.4	CNS Stimulants and drugs used for attention deficit hyperactivity disorder			
				NICE TA98: Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine NICE CG 72: ADHD C&W APC drug positioning statement for Lisdexamfetamine July 2013 ESCA Atomoxetine November 2009 ESCA Dexamphetamine November 2009 ESCA Lisdexamfetamine July 2013 ESCA Methyl phenidate November 2009
		1st line	Methylphenidate Tablets (Immediate release) CD SC	
		1st line	Medikinet XL Capsules (50% IR/ 50% XL), Equasym XL Capsules (30% IR/ 70% XL). (Methylphenidate Tablets (slow release))	
		2nd line	Concerta XL (22% IR/ 78% XL).	
			Modafinil Tablets SA	MHRA advice: Modafinil restriction to narcolepsy
4.5	Drugs used in the treatment of obesity			
	4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract		Orlistat Capsules	NICE CG43: Obesity
	4.5.2 Centrally acting appetite suppressants			
4.6	Drugs used in nausea and vertigo			
		Antihistamines		
			Cinnarizine Tablets	
			Cyclizine Tablets, Injection	
			Promethazine Hydrochloride Tablets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		Phenothiazines and related drugs		West Midlands Palliative Care Guidelines.
			Chlorpromazine (See BNF section 4.2.1)	
			Prochlorperazine Tablets, Buccal Tablets, Injection (IM only)	
		Domperidone and metoclopramide		
			Domperidone Tablets, Suspension	MHRA advice: Domperidone
			Metoclopramide Tablets, Liquid, Injection	MHRA advice: Metoclopramide
		5HT3 antagonists		MHRA advice: Ondansetron (Zofran): risk of QT prolongation – important new intravenous dose restriction.
			Ondansetron Tablets, Injection SO (For various chemotherapy, radiotherapy, post operative indications).	
			Ondansetron Tablets, Injection SA (Unlicensed use in pregnancy, longer term use in cancer patients)	
		Neurokinin receptor antagonist		
			Aprepitant Capsules 3 day pack SO (Restrict to Cancer Network)	
			Fosaprepitant Injection 150mg SO (Restrict to Cancer Network)	
		Hyoscine		Hyoscine hydrobromide for motion sickness and salivation. Pre medication, by S/C or I/M 200mcg - 600mcg before anaesthesia. UKMI QA: Hypersalivation – can hyoscine hydrobromide be used to treat it? UKMI QA: Hypersalivation - what drug treatment options are available? Motion sickness.
			Hyoscine hydrobromide Tablets 150mcg and 300mcg	
			Hyoscine hydrobromide Patch 1mg/72 hrs	NB Hyoscine Butylbromide for smooth muscle spasms not secretions.
			Hyoscine hydrobromide Injection 400mcg/ml, 600mcg/ml (Also see BNF 15.1.3)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		Others for Meniere's Disease		
			Betahistine Tablets	
4.7	Analgesics			MHRA advice: new paracetamol dosing for children. WHO Pain Ladder. NICE CG88: Low back pain. C&W APC Pain Guidelines: pain management, July 2010. C&W APC Pain Guidelines: pain medication algorithm July 2010.
4.7.1	Non opioid			C&W APC MM team preferred prescribing choices.
			Aspirin Tablets, Soluble Tablets, E/C 75mg, 300mg	
			Aspirin Suppositories 150mg, 300mg	
			Paracetamol Tablets, Soluble Tablets	
			Paracetamol Oral Suspension 120mg/5ml, 250mg/5ml	
			Paracetamol Suppositories 60mg, 125mg, 240mg, 500mg	
			Paracetamol IV Infusion 10mg/ml 50ml, 100ml Vial	
			Co-codamol 8/500 Tablets, Effervescent Tablets	
			Co-codamol 30/500 Tablets, Effervescent Tablets, Capsules	
			Co-codamol 15/500 Tablets	
			Co-dydramol Tablets	
	Mild opiates			
			Codeine Tablets 15mg, 30mg, 60mg	
			Dihydrocodeine Tablets 30mg	
			Dihydrocodeine 10mg in 5ml Elixir R (To patients with swallowing difficulties)	
			Tramadol 50mg Capsules CD	
			Tramadol Tablets MR 100mg, 200mg CD	
			Tramadol 100mg/2ml Injection CD	
				C&W APC says avoid using ibuprofen MR products, COXIBs if CV risk and Diclofenac if high CV risk.

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
4.7.2	Opioid			NPSA: Ensuring safer practice with high dose ampoules of diamorphine and morphine May 2006. NPSA alert: Reducing dosing errors with opioid medicines July 2008. MHRA Fentanyl patches: serious and fatal overdose from dosing errors, accidental exposure, and inappropriate use September 2008. NICE CG140: Opioids in palliative care May 2012. The British Pain Society: Opioids for persistent pain: Good practice
		Diamorphine	Diamorphine 5mg Injection CD	
		Buprenorphine		
		Weekly	Buprenorphine 5mcg, 10mcg, 20mcg Patches CD	
		4 day (96hr) Patch	Buprenorphine Patches 35mcg, 52.5mcg, 70mcg CD	
		Fentanyl		
			Fentanyl S/L Tablets (Abstral) SI (Palliative care) CD	C&W APC says discouraged except if patient meets certain criteria in palliative care and is initiated by Palliative Care Specialist or Macmillan Nurses.
			Fentanyl Patches CD	MHRA Fentanyl patches: serious and fatal overdose from dosing errors, accidental exposure, and inappropriate use September 2008.
			Fentanyl 2mcg/ml + Bupivacaine 0.1% (Epidural Bag) CD	
		Morphine		
		Immediate release Morphine		
			Morphine sulphate 10mg/5ml Oral Solution	
			Morphine sulphate 100mg/5ml Concentrated Oral Solution R (High dose Opiate) CD	
			Morphine Immediate Release Tablets (Sevredol) CD	
			Morphine Injection CD	
		Modified release Morphine		

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		Morphgesic (12hrly)	Morphine SR Tablets (Morphgesic) CD	
		MST (12hrly)	Morphine SR Tablets (MST) 5mg, 15mg Strengths only (MST restricted. Use Morphgesic brand as more cost effective) CD	
		Zomorph (12hrly)	Morphine SR Capsules (Zomorph) CD	
			Cyclimorph 10 Injection CD	
			Cyclimorph 15 Injection CD	
			Morphine 100mg/100mls 0.9% Sodium Chloride (PCA) CD	
		Oxycodone		C&W APC says use oxycodone on advice from Palliative Care Specialist and Macmillan Nurses
		Immediate release Oxycodone		
			Oxycodone 5mg/5ml Liquid CD	
			Oxycodone 10mg/ml Conc Solution R (High dose opiate) CD	
			Oxycodone Capsules CD	
			Oxycodone 10mg in 1ml Injection CD	
		Modified release-Oxycodone		
			Oxycodone SR Tablets CD	
			Oxycodone/naloxone MR Tablets R (Palliative care) CD	
			Pethidine 50 mg in 1mL Injection CD	
4.7.3	Neuropathic			NICE CG 96: Neuropathic pain Mar 2010
			Duloxetine Capsules (Cymbalta) SC	ESCA Duloxetine May 2011. C&W APC drug positioning statement for Duloxetine May 2011.
			Amitriptyline Tablets (Unlicensed)	
			Nortriptyline Tablets (Unlicensed)	
			Gabapentin Capsules	
			Pregabalin Capsules	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Tramadol Capsules CD	
			Lidocaine 5% Patches R (Specialist, palliative care specialist and pain team, Licensed for post hepatic neuralgia but not other neuropathic conditions)	
			Capsaicin 0.075% Cream R (Licensed in post herpetic neuralgia and diabetic neuropathy)	
			Morphine R CD (Restricted in neuropathic pain. To be prescribed by specialist neurologist or palliative care specialist)	
			Oxycodone CD R (Restricted in neuropathic pain. To be prescribed by specialist neurologist or palliative care specialists)	
			Carbamazepine R (Restricted when indicated for trigeminal neuralgia. To be prescribed by specialist neurologist or palliative care specialist)	
			Phenytoin R (Restricted when indicated for trigeminal neuralgia. To be prescribed by specialist neurologist or palliative care specialist.)	
4.7.4	Anitmigraine drugs			
4.7.4.1		Treatment of the acute migraine attack		
			Ibuprofen (+/- antiemetic (Metoclopramide or Domperidone tablets. See BNF section 10.1.1)	NICE CG 150: Headaches: Diagnosis and management of headaches in young people and adults
			Paracetamol (Also See BNF section 4.7.1)	
			Naproxen (See BNF section 10.1.1)	
			Sumatriptan Tablets, 6mg in 0.5ml Syringe	
4.7.4.2	Prophylaxis of migraine			
		1st line	Propranolol modified release/long acting Capsules	
			Pizotifen 500mcg and 1.5mg Tablets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
4.7.4.3	Cluster headache and trigeminal autonomic cephalalgias			
4.8	Antiepileptic drugs			
4.8.1	Control of epilepsies			
			Carbamazepine SA R (For Neurologist initiation or continuation if patients admitted on drug).	NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care January 2012. MHRA Advice: St John's Wort: interactions with all antiepileptics
			Gabapentin SA R (For Neurologist initiation or continuation if patients admitted on drug).	MHRA Advice: Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions associated with the HLA-A* 3101 allele.
			Pregabalin SA R (For Neurologist initiation or continuation if patients admitted on drug).	
			Lamotrigine SA R (For Neurologist initiation or continuation if patients admitted on drug).	
			Levetiracetam SA R (For Neurologist initiation or continuation if patients admitted on drug).	
			Primidone SA R (For Neurologist initiation or continuation if patients admitted on drug).	
			Phenytoin Capsules 30mg/5ml Suspension SA (For Neurologist initiation or continuation if patients admitted on drug).	
			Phenytoin 90mg/5mL Suspension (Special)	
			Phenytoin Injection IV	
			Phenobarbitone SA CD (For Neurologist initiation or continuation if patients admitted on drug).	
			Topiramate SA (For Neurologist initiation or continuation if patients admitted on drug)	
			Na Valproate SA R (For Neurologist initiation or continuation if patients admitted on drug).	
			Clobazam Tablets SA	
			Clonazepam Tablets, Oral Solution SA	
4.8.2	Drugs used in status epilepticus			
			Diazepam Injection IV	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Diazepam Rectal Solution	
			Lorazepam InjectionIV	
			Midazolam 5mg/ml Oral Solution CD	
4.8.3	Febrile convulsions			
4.9	Drugs used in parkinsonism and related disorders			Patients with suspected Parkinson's disease should be referred to a specialist to confirm the diagnosis. NICE CG 35: Parkinsons Disease
		Dopamine Receptor Agonist (Monotherapy or with levodopa).		MHRA Advice: Dopamine agonists: pathological gambling, increased libido, and hypersexuality.
			Pramipexole Tablets and MR Tablets SA	
			Ropinirole Tablets and MR Tablets SA	
			Rotigotine Patches SA	
			Apomorphine 50mg in 10mL Pre-filled Syringe SC (Restrict to patients admitted on drug).	
		Levodopa with Dopa Decarboxylase		
			Co-beneldopa Capsules, Capsules M/R, Dispersible Tablets SA	UKMI Q&A: Guidance on converting from MR formulation to dispersible tablets
			Co-careldopa Tablets, MR Tablets SA	
		Monoamine oxidase B Inhibitors	Monotherapy or be used with levodopa	
			Rasagiline 1mg Tablets SA	
			Selegiline Tablets	
			Stalevo Tablets (co-careldopa and entacapone). SA	
		COMT		Also licensed for use with co-beneldopa or co-careldopa
			Entacapone Tablets SA	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		Dopamine agonist	Amantadine Capsules, Syrup SA	
		Antimuscrinics		
			Procyclidine Tablets, Elixir, Injection R (Not to be used for Parkinsons disease. Restrict to drug-induced extrapyramidal symptoms but not tardive dyskinesia).	
4.9.3		Essential tremor, chorea, tics and related disorders		
		Torsion dystonias and other involuntary movements		
			Botulinum Toxin Injection A SO (Indicated for dystonia and spasticity management. Not routinely commissioned for the following conditions wrinkles, hyperhidrosis, overactive bladder, anal fissure).	
			Botulinum Toxin Injection B SO (Indicated for dystonia and spasticity management. Not routinely commissioned for the following conditions wrinkles, hyperhidrosis, overactive bladder, anal fissure).	
4.10	Drugs used in substance dependence			
	Alcohol dependence	Alcohol relapse prevention		
			Acamprosate Tablets SC (Restricted for maintenance in patients admitted on drug)	Drug Misuse and Dependence: UK Guidelines on Clinical Management (Orange Guideline). ESCA - Acamprosate May 2011.
			Naltrexone Tablets SC (Restricted for maintenance in patients admitted on drug).	NICE TA115 Naltrexone for the management of opioid dependence Jan 2007
			Disulfiram Tablets SC (Restricted for maintenance in patients admitted on drug).	ESCA Disulfiram March 2011

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		Alcohol detoxification		
			Chlordiazepoxide Capsules 5mg, 10mg	
			Thamine 100mg Tablets	
			Vitamin B Co Forte Tablets	
			Pabrinex IV Injection	
			Ascorbic Acid Tablets	
	Nicotine dependence			
				NICE TA123: Varenicline Smoking cessation services NICE PH10: Smoking cessation during pregnancy and after childbirth NICE PHG1: Brief interventions and referral for smoking cessation. NICE PHG10: Smoking Cessation Services
			Nicotine Replacement Treatment Transdermal Patches	
	Opioid dependence	Opioid dependence		
				NICE: TA114: Methadone and buprenorphine for the management of opioid dependence. NPSA/2008/RRR/05 Reducing dosing errors with opioid medicines. NICE TA115: Naltrexone for the management of opioid dependence January 2007
		1st line	Methadone 1mg in 1ml Mixture CD	
		2nd line	Buprenorphine S/L Tablets 2mg, 8mg SC CD (Restricted for maintenance in patients admitted on drug)	NICE TA114: Methadone & buprenorphine for the management of opioid dependence January 2007 NPSA/2008/RRR/05 reducing dosing errors with opioid medicines
		2nd line	Buprenorphine 2mg /naloxone, 500 microgram, 8mg/ 2mg (Suboxone) R CD (Restricted for maintenance in patients admitted on drug)	
				NICE TA114: Methadone & buprenorphine for the management of opioid dependence Lofexidine is a non opioid alpha- adrenergic and not a CD
			Naltrexone SC R (for maintenance in patients admitted on drug)	
			Methadone 50mg in 5ml Solution R (Pain team only) CD	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
4.11	Drugs for dementia			NICE CG42: Dementia NICE TA217: Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine ESCA for donepezil, galantamine, rivastigmine, and memantine. February 2012. C&W APC - Prescribing Checklist: use in dementia. NICE TA292: Aripiprazole in Bipolar Disorder
		1st line	Donepezil SC Tablets, Orodispersible Tablets	
		1st line	Galantamine Tablets, MR Capsules SC	
			Galantamine 4mg/1ml SC Solution	
		1st line	Rivastigmine Capsules SC	
			Rivastigmine Patches 4.6mg, 9.5mg patches SC	
<p><u>Discouraged list</u> - APC. tapentadol SR and MR - discouraged list, fentanyl immediate release tablets, fentanyl immediate release lozenges, fentanyl immediate release nasal spray, Sativex not recommended (10.2.2), co-proxamol, paracetamol and tramadol, oxycodone and naloxone. (tramacets), patches unless oral route is suitable, , MXL brand, MST, COXIBs if CV risk, Diclofenac if high CV risk, ibuprofen MR preps, tramadol MR products, paracetamol/co-codamol soluble tablets, morphine suppos, Qutenza (capsaicin 8%).</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
5.1	Antibacterial drugs			SWFT Antibiotic Prescribing Clinical Guidelines.
5.1.1	Penicillins			
5.1.1.1	Benzylpenicillin and phenoxymethyl penicillin			
			Benzylpenicillin Injection	
			Phenoxymethylpenicillin Tablets, Syrup	
			Benazathine Benzylpenicillin Injection. R (To GUM or if recommended by microbiology).	
5.1.1.2	Penicillinase-resistant penicillins			
			Flucloxacillin Capsules, Syrup, Injection	
5.1.1.3	Broad-spectrum penicillins			
			Amoxicillin Capsules, Injection	
			Co-amoxiclav Tablets, Dispersible Tablets, Injection R (Use within antibiotic guidelines due to increased C Diff risk)	
5.1.1.4	Antipseudomonal penicillins			
			Piperacillin/Tazobactam Injection R (Use within antibiotic guidelines)	
5.1.1.5	Mecillinams			
5.1.2	Cephalosporins and other beta lactams			
5.1.2.1	Cephalosporins			
			Cefalexin Capsules, Syrup, Tablets R (Use as per antibiotic guidelines or with microbiology advice. Increased risk of C Diff).	
			Cefotaxime Injection R (Use as per antibiotic guidelines or with microbiology advice. Increased risk of C Diff).	
			Ceftriaxone Injection R (Use as per antibiotic guidelines or with microbiology advice. Increased risk of C Diff).	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Ceftazidime Injection SO (Use as per antibiotic guidelines or with microbiology advice. Increased risk of C Diff).	
			Cefuroxime Injection, Tablets, Suspension R (Use as per antibiotic guidelines or with microbiology advice. Increased risk of C Diff).	
5.1.2.2	Carbapenems			
			Ertapenem Injection SO (Use as per antibiotic guidelines or with microbiology advice. Increased risk of C Diff).	
			Meropenem Injection SO (Use as per antibiotic guidelines or with microbiology advice. Increased risk of C Diff).	
5.1.2.3	Other beta-lactam antibiotics			
5.1.3	Tetracyclines			
			Doxycycline Capsules	
			Minocycline Capsules R (Restrict to dermatology).	
			Oxytetracycline tabs	
			Tigecycline Injection R (Use only with microbiology advice - cost and safety concerns)	
5.1.4	Aminoglycosides			
			Gentamicin Injection	
			Amikacin Injection R (Use only with microbiology advice)	
5.1.5	Macrolides			
			Azithromycin Capsules, Suspension	
			Erythromycin Tablets	
			Clarithromycin Injection, Tablets, Suspension, Sachets	
5.1.6	Clindamycin			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Clindamycin Capsules, Injection R (Use as per antibiotic guidelines or with microbiology advice. Increased risk of C Diff).	Use as per antibiotic guidelines or with microbiology advice. Increased risk of C Diff
5.1.7	Other Antibiotics			
			Chloramphenicol Capsules, Injection R (To meningitis or microbiology advice).	
			Sodium Fusidate Tablets	
			Vancomycin Capsules R (Restrict capsules for TTOs only in C Diff).	
			Vancomycin Injection	
			Teicoplanin Injection SO	
			Daptomycin Intravenous Infusion SO (Use with microbiology advice)	
			Linezolid Intravenous Infusion, Tablets SO (Use with microbiology advice. Cost and safety).	
			Colistimethate Sodium Injection SA (Restrict to specialist and microbiology advice).	NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
5.1.8	Sulphonamides and Trimethoprim			
			Co-trimoxazole Tablets, Suspension, Injection R (Specialist advice or with microbiology advice).	
			Trimethoprim Tablets, Suspension	
5.1.9	Anti-tuberculosis Drugs		All anti-tuberculosis drugs below are restricted to microbiology approval or for use under respiratory or HIV consultants only.	
			Ethambutol Tablets SO R (See above)	
			Isoniazid SO R (See above)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Pyrazinamide Tablets SO R (See above)	
			Rifabutin Capsules SO R (See above)	
			Rifampicin Capsules, Syrup, Injection SO R (See above) Enzyme inducer	
5.1.10	Antileptotics			
			Dapsone Tablets SA R (Specialist and/or microbiology advice)	
5.1.11	Metronidazole and Tinidazole			
			Metronidazole Tablets, Suspension, Infusion, Suppositories	
5.1.12	Quinolones			
			Ciprofloxacin Tablets, Syrup, Injection R (Restricted due to high risk of C. Diff and induction of antibiotic resistance. Use within guidelines &/or microbiology advice).	
5.1.13	Urinary-tract Infections			
			Nitrofurantoin Tablets, Capsules, Suspension R (Contraindicated if GFR>60mls/min. MHRA Drug Safety Update Aug 13)	
5.2.1	Triazole antifungals			
			Fluconazole Capsules, Suspension, Injection	
			Itraconazole Capsules, Liquid	
			Posaconazole Suspension SO R (High cost. Use with advice from microbiology or haematology specialist).	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Voriconazole Tablets Injection SO R (High cost. Use with advice from microbiology or haematology specialist).	
5.2.2	Imidazole antifungals		Ketaconazole	
5.2.3	Polyene antifungals		Amphotericin SO (lipid) R (High cost. Use with advice from microbiology or haematology).	
5.2.4	Echinocandin antifungals		Caspofungin Injection R (High cost. Use with advice from microbiology or haematology specialist).	
5.2.5	Other antifungals		Terbinafine Tablets	
5.3	Antiviral Drugs		HIV antivirals are restricted to HIV specialist.	
5.3.1	HIV infection		Abacavir SO R (Restrict to specialist).	
			Abacavir with lamivudine (kivexa) SO- R (Restrict to specialist).	
			Abacavir/ Lamivudine/ Zidovudine (trizvir) SO R (Restrict to specialist).	
			Atazanavir (reyataz) SO R (Restrict to specialist).	
			Darunavir SO R (Restrict to specialist).	
			Didanosine SO R (Restrict to specialist).	
			Efavirenz SO R (Restrict to specialist).	
			Etravirine SO R (Restrict to specialist).	
			Lamivudine SC R (Restrict to specialist).	
			Lamivudine SO R (Restrict to specialist).	
			Lopinavir with Ritonavir SO R (Restrict to specialist).	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Nevirapine SO R (Restrict to specialist).	
			Raltegravir SO R (Restrict to specialist).	
			Ritonavir SO R (Restrict to specialist).	
			Tenofovir with emtricitabine (Truvada® brand) SO R (Restrict to specialist).	
			Zidovudine SO R (Restrict to specialist).	
			Zidovudine/ lamivudine (Combivir) SO R (Restrict to specialist).	
5.3.2	Herpesvirus infections			
5.3.2.1	Herpes simplex and varicella-zoster infection			
			Aciclovir Dispersible Tablets, Suspension, Infusion, Eye Ointment	
			Famciclovir Tablets	
5.3.3	Viral hepatitis			
5.3.3.2	Chronic hepatitis C			
			Tenofovir disoproxil Tablets	
			Boceprevir Capsules	
5.3.4	Influenza			
5.3.5	Respiratory syncytial virus			
			Palivizumab Injection SO R (Restrict to specialist or use with advice from microbiologist only).	
			Ribavirin Capsules, Tablets SO R (Restrict to specialist or use with advice from microbiologist only).	
5.4.4	Antigiardial			
			Mepacrine Tablets R	
5.4.8	Drugs for pneumocystis pneumonia			
			Atovaquone R (To HIV and respiratory consultants where Co-trimoxazole or Dapsone isn't tolerated).	
5.5.1	Drugs for threadworms			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Mebendazole Tablets	
5.5.2	Ascaricides			
			Levamisole R	
<u>Discouraged List</u>				
<p>Minocycline, Minocycline MR, (Aknemin[®], Blemix[®], Sebomin MR[®], Acnamino MR[®], Minocin MR[®]) Although minocycline has a broader spectrum than the other tetracyclines (offers active against Neisseria meningitidis), it is no longer recommended because of side-effects including dizziness, vertigo, a greater risk of lupus-erythematosus like syndrome and irreversible pigmentation. Safer and more cost-effective treatments for acne are available. Advice from APC is to use doxycycline, lymecycline and oxytetracycline.</p>				
<p>Avloclor, (Malarivon, Nivaquine), Malarone[®], Lariam[®], Riamet[®], Primaquine (Generic), Paludrine[®], Daraprim[®], Fansidar[®], Deteclo[®] - Should not be prescribed by NHS for malaria prophylaxis - Offer private prescription.</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
6.1	Diabetic drugs			
				NHS Diabetes guidance - Safe and effective use of insulin in hospitalised Patients Mar 2010 www.diabetes.nhs.uk NICE CG 15: Type 1 diabetes in adults and children and young people. 2004 NICE TA151: Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) Jul 2008 NPSA/2010/RRR013 Rapid response report Safer Administration of Insulin NPSA Insulin Passport Mar 2011 NICE CG66 Type 2 diabetes: Full guideline May 2008.
6.1.1.1	Short Acting Insulins	Neutral insulin		
			Hypurin Bovine R Cartridge, Vial (Specialist/Diabetic team)	
			Hypurin Porcine R Cartridge, Vial (Specialist/Diabetic team)	
			Actrapid Vial	
			Humulin S Cartridge, Vial	
			Aspart Vial, Penfill Cartridge, Flexpen, Vial	
			Glulisine Vial, Clickstar Cartridge, Solostar pen	
			Humalog (Lispro) Vial, Cartridge, Kwikpen	
	Intermediate and Long Acting	Intermediate		
			Insulatard Penfill Cartridge, Vial, Innolet	
			Humulin I Vial, Cartridge, Kwikpen	
		Biphasic		

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Humulin M3 Vial, Cartridge, Kwikpen	
			Novomix 30 Cartridge, Flexpen	
			Humalog Mix 25 Cartridge, Vial, Flexpen	
			Humalog Mix 50 Cartridge, Vial, Flexpen	
		Long acting		NICE TA 53: Diabetes (Types 1 and 2) - long acting insulin analogues
			Detemir Innolet, Flexpen, Cartridge	
			Glargine Vial, Clickstar Cartridge, Solostar Pen	
			Hypurin Bovine Lente Vial R (Specialist/Diabetic team)	
			Hypurin Porcine Isophane Vial, Cartridge R (Specialist/Diabetic team)	
6.1.1.3	Hypodermic Equipment			C&W APC Blood Glucose Testing Strips - Chart: self monitoring of blood glucose in type 2 diabetes
6.1.2.1	Antidiabetic	Sulphonylureas		NICE CG87: May 2009 - Type 2 diabetes: The management of type of 2 diabetes. NICE CG87: Type 2 Diabetes - Newer agents Mar 2009 NICE CG63: Diabetes in pregnancy 2008 Diabetes - Guidelines: type 2 diabetes prescribing
		1st line	Gliclazide 80mg Tablets	C&W APC
		1st line	Glimepiride Tablets	
			Gliclazide 30mg MR Tablets	
			Glibenclamide Tablets	
			Glipizide Tablets R (Specialist/Diabetic team)	
			Tolbutamide Tablets R (Specialist/Diabetic team)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
6.1.2.2		Biguanides		
		1st line	Metformin Tablets	
			Metformin MR Tablets	
			Metformin Oral Powder	
			Metformin Solution R (Specialist/Diabetic team)	
6.1.2.3		Other diabetic drugs		
			Dapagliflozin Tablets R (Any prescriber but under specialist advice if triple therapy or used with insulin)	NICE TA 288: Type 2 diabetes - Dapagliflozin combination therapy Jun 2013
			Canagliflozin Tablets R (Any prescriber but under specialist advice (SA) if used with insulin)	
		Thiazolidinediones (Glitazones)		MHRA/CHM advice - Pioglitazone cardiovascular safety (Dec2007 and Jan 2011) Pioglitazone: risk of bladder cancer Jul 2011 C&W APC Pioglitazone generic - Urgent bulletin Mar 2012
			Pioglitazone Tablets	
		DPP-4 Inhibitors Gliptins		MHRA Advice: Dipeptidylpeptidase-4 inhibitors ('gliptins'): risk of acute pancreatitis Sept 2012 C&W APC DPP-4 inhibitors - Drug Comparison Chart C&W APC Saxagliptin - Drug Positioning Statement: type 2 diabetes mellitus
		1st line	Sitagliptin Tablets	
		2nd line	Linagliptin Tablets	
		GLP -1 s		
		1st line	Exenatide Prefilled Injection SA (Specialist/Diabetic team)	C&W APC GLP-1s - Drug Comparison Chart

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		1st line	Liraglutide Prefilled Injection SA (Specialist/Diabetic team)	NICE TA203: Liraglutide : quick reference guide Oct 2010
		1st line	Lixisenatide Prefilled Injection R (Specialist/Diabetic team)	C&W APC Lixisenatide - Interim Positioning Statement: type 2 diabetes
		2nd line	Exenatide Prefilled Injection PR Injection with insulin SA (Specialist/Diabetic team)	NICE TA248: Exenatide (prolonged release) Feb 2012
6.1.3	Diabetic Ketoacidosis	n/a		
			Glucagon Injection	
			Glucose IV (See chapter 9.2.2.1)	
			Glucose Oral	
			Glucogel, Dextrogl	
6.1.4	Hypoglycaemia			
6.1.5	Diabetic Nephropathy			NICE CG87: May 2009 - Type 2 diabetes: The management of type of 2 diabetes.
	Neuropathy		Also see BNF Section 4.7.3	WHO pain ladder NICE CG96: Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings Mar 2010
6.2.1	Thyroid and Antithyroid drugs			
		Thyroid	Levothyroxine Tablets	Royal College of Physicians statement: The Diagnosis and Management of Primary Hypothyroidism
			Levothyroxine Injection R (Specialist)	
			Liothyronine Tablets SI	
			Liothyronine Injection SI R (Specialist)	
6.2.2	Antithyroid	Antithyroid		

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Carbimazole Tablets	
			Propylthiouracil Tablets and IV	
			Aqueous Iodine Oral Solution	
6.3	Corticosteroids			ADSH Surgical Guidance
6.3.1	Replacement therapy			
			Fludrocortisone Acetate Tablets	
6.3.2	Glucocorticoid	Steroid		
			Betamethasone Soluble Tablets 500mcg	
			Betamethasone Injection 4mg/ml	
			Dexamethasone Tablets	
			Dexamethasone Oral Solution 2mg/5ml	
			Dexamethasone Injection 4mg/ml	
			Hydrocortisone Tablets	
			Hydrocortisone Sodium Succinate Injection (Sol-cortef)	
			Methylprednisolone acetate Injection (Solu-Medrone) 40mg, 125mg, 500mg, 1G	
			Methylprednisolone (Depo-medrone) 40mg in 1ml, 2ml	
			Prednisolone Tablets, Soluble Tablets	
6.4.1	Female Sex Hormones and their modulators			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
6.4.1.1	Oestrogens and HRT		HRT preparations R (Restricted to patients that are admitted on HRT preparations. Not to be initiated unless under the directions of an endocrinologist or gynaecological specialist).	MHRA and CHM. Hormone-replacement therapy: updated advice. & Tibolone: benefit-risk balance . Drug Safety Update 2007; 1(2): 2-6 NPCi: Data focussed commentary - HRT
			Estradiol 50 mcg Patch	MHRA Volume 7, Issue 7 Feb 2014, Combined hormonal contraceptives and venous thromboembolism: review confirms risk is small
			Estriol (Ovestin) 0.1% Vaginal Cream	
			Estradiol (Oestrogel) 0.06% Gel	
			Estriol 500mcg Pessaries	
			Estradiol (Sandrena) 0.1% Gel	
			Raloxifene Tablets	
6.4.1.2	Progesterone and Progesterone Receptor Modulators		Northisterone Tablets 5mg	NICE CG44: Heavy menstrual bleeding
			Medroxyprogesterone 10mg Tablets	
			Medroxyprogesterone acetate Injection	
			Tibolone Tablets	
6.4.2	Male Sex Hormones and Antagonists		Testosterone Gel 50mg/5g tube (Testogel) SC	
			Testosterone Gel 50mg/5g tube (Testim) SC	
			Testosterone 2% Gel (Tostran) SC	
			Testosterone 1000mg/4ml (Nebido) (Specialist)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Testosterone 40mg Capsules (Specialist)	
			Cyproterone acetate Tablets 100mg (Specialist)	
		5 Alpha Reductase Inhibitors		
		1st line	Finasteride Tablets	NICE CG97: Lower urinary tract symptoms: May 2010
			Dutasteride Capsules	
			Sustanon 100 and 250 (Specialist)	
			Testosterone Undecanoate Capsules 40mg (Specialist)	
6.4.3	Anabolic Steroids			
6.5.1	Hypothalamic and Anterior Pituitary Hormones and Anti-oestrogens			
		Anti-oestrogens		
			Clomiphene Tablets 50	
		Anterior Pituitary Hormones		
			Tetracosactide 250mg/ml Injection	Position statement from the Society for Endocrinology on the use of Synacthen in patients with asthma
		Growth Hormone		NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (May 2010) NICETA64: Human growth hormone (somatropin) in adults with growth hormone deficiency Aug 2003
			Somatropin Injection 4mg (12 units) SC	ESCA - Somatropin - Shared Cared Agreement: for deficiency of growth hormone in children Sept 2012.

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
6.5.2	Post Pituitary Hormones and Antagonists	Posterior Pituitary Hormones	Desmopressin Tablets SA	
			Desmopressin 10mcg/ml Nasal Spray	
			Terlipressin 0.12mg/ml Injection	NICE CG 141: Acute upper GI bleeding Jun 2012
		Antidiuretic Hormone Antagonists		
			Demeclocycline 150mg Capsules	
			Tolvaptan Tablets (Specialist)	
6.6	Drugs affecting bone metabolism			
6.6.1		Calcitonin and Parathyroid Hormone		
			Calcitonin Injection SO (Osteoporosis)	
			Calcitonin Injection SO (Pagets)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
6.6.2		Bisphosphonates		<p>NICE TA160: Osteoporosis - primary prevention: guidance Jan 2011. EMEA: CHMP Assessment report on bisphosphonates and osteonecrosis of the jaw. NICE TA161: Osteoporosis - secondary prevention including strontium ranelate: guidance Jan 2011. Oral Health Management of Patients Prescribed Bisphosphonates: Dental Clinical Guidance. Scottish Dental Clinical effectiveness Programme. Apr 2011. MHRA/CHM Bisphosphonates; atypical femoral fractures Jun 2011. MHRA advice: Bisphosphonates and oesophageal cancer risk Nov 2010. MHRA Advice: important safety information for bisphosphonates</p>
		1st line	Alendronic Acid Tablets	
		1st line	Alendronic Acid 70mg/100ml Solution (Specialist)	
		2nd line	Risedronate Tablets 35mg (Weekly)	
			Risedronate Tablets 5mg (Daily) (Specialist)	
			Disodium Pamidronate Injection 50	
			Ibandronic Acid Tablets 150mg	
			Ibandronic Acid Tablets 50mg SC (For reduction of bone damage in bone metastases in breast cancer)	ESCA - Ibandronic acid - Shared Care Agreement:for skeletal events in metastatic breast cancer, Feb 2013.
			Sodium Clodronate SA	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Zoledronic Acid 5mg IV Infusion SO	
			Zoledronic Acid 4mg IV Infusion SO (Indicated in bone malignancies see BNF Chapter 8 and MOSAIQ)	
			Denosumab Injection 70mg/ml SO (Reduction in bone damage in those with metastases from solid tumours)	Reduction in bone damage in those with metastases from solid tumours. NICE TA265: Denosumab for the Prevention of Skeletal Related Events in Adults with Bone Metastases from Solid Tumours Oct 2012. MHRA Advice: Denosumab: fatal cases of severe symptomatic hypocalcaemia, and risk of hypocalcaemia at any time during treatment – monitoring recommended.
			Denosumab 60mg/ml Prefilled Syringe SA (In treatment of post menopausal osteoporosis)	NICE TA204: Denosumab for the Prevention of Osteoporotic Fractures in Postmenopausal Women Oct 2010.
			Strontium Granules	MHRA- Strontium ranelate (Protelos): should not be used in patients with current or previous venous thromboembolism (VTE) or temporary or permanent immobilisation because of risk of VTE. Rare serious skin reactions may occur within the first weeks of treatment Volume 5, Issue 10 May 2012. MHRA - Strontium ranelate (Protelos): risk of serious cardiac disorders, restricted indications, new contraindications, and warnings Volume 6, Issue 9 Apr 2013. C&W APC Strontium - Urgent Bulletin CV disease risk.

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
6.7	Other Endocrine drugs			
6.7.1	Bromocriptine and other Dopaminergic Drugs			
			Bromocriptine Tablets SA	
			Cabergoline Tablets SA	
6.7.2	Drugs affecting gonadotrophins			
			Leuprorelin acetate Injection SA (Endometriosis)	
			Leuprorelin acetate Injection SO (Endometrial preparation prior to surgery)	
			Goserelin Injection SA (Endometriosis)	
			Goserelin Injection SO (Endometrial preparation prior to surgery)	
6.7.3	Metyrapone		Metyrapone Capsules (Specialist)	
<p><u>Discouraged Drugs</u>. Alendronic acid with Colecalciferol (Fosavance®), Testosterone patch (Intrinsa) - Testosterone patches for women not recommended. Hypoactive sexual desire disorder assoc with surgical induced menopause (in women receiving concomitant oestrogen therapy). Thyroid extracts / levothyroxine + T3 combinations. Ibandronic acid Monthly formulations (Bonviva® 150mg), Risedronate with Calcium and Colecalciferol (Actonel Combi®).</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
7.1	Drugs used in Obstetrics			
7.1.1	Prostaglandins and Oxytocics			
			Carboprost Injection 250 micrograms/ml 1ml Dinoprostone Pessaries 3mg	NICE CG55: Intrapartum care Induction of labour NICE CG132: Caesarean section NICE CG70: Ectopic pregnancy and miscarriage
			Ergometrine Injection 500 micrograms/ml 1ml Oxytocin 5 units/ml, Ergometrine 500 mcg/ml 1ml (Syntometrine Injection)	
			Oxytocin Injection 5 units/ml 1ml, 10 units/ml, 1ml	
7.1.1.1	Drugs affecting the ductus arteriosus			
7.1.2	Mifepristone		Mifepristone Tablets 200mg	
7.2	Treatment of Vaginal and Vulval Conditions			
7.2.1	Preparations for Vaginal Atrophy			
			Estriol Intra Vaginal Cream 0.01% (Gynest) Estradiol Vaginal 10mcg, 25mg Tablets (Vagifem) Acetic acid 5% Solution (Unlicensed)	
7.2.2	Vaginal and Vulval Infections			
			Clotrimazole 1% Cream Clotrimazole Pessaries 100mg Clotrimazole Pessaries 500mg Canestan HC Cream Metronidazole 0.75% Vaginal Gel R	
7.3	Contraceptives			Faculty of Sexual & Reproductive Healthcare website Medical Eligibility Criteria for Contraceptive Use UK NICE CG30: Long-acting reversible contraception
7.3.1	Combined Hormonal Contraceptives			
		Brevinor	Ethinylestradiol 35mcg & Norethisterone 500 Tablets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		Co-cyprindiol 30/150, (Gedarel)	Ethinylestradiol 30mcg & Desogestrel 150 Tablets	
		Femodette	Ethinylestradiol 20mcg & Gestodene 75mcg Tablets	
		Cilest	Ethinylestradiol 35mcg & Norgestimate 250mcg Tablets	
		Femodene	Ethinylestradiol 30mcg & Gestodene 75mcg Tablets	
		Femodene ED	Ethinylestradiol 30mcg & Gestodene 75mcg Tablets	
		Loestrin 20	Ethinylestradiol 20mcg & Norethisterone 1.0mg Tablets	
		Loestrin 30	Ethinylestradiol 30mcg & Norethisterone 1.5mg Tablets	
		Logynon	Ethinylestradiol 30mcg & Levonorgestrel 50mcg Tablets	
		Logynon ed	Ethinylestradiol 30mcg & Levonorgestrel 50mcg Tablets	
		Marvelon	Ethinylestradiol 30mcg & Desogestrel 150mcg Tablets	
		Mercilon	Ethinylestradiol 20mcg & Desogestrel 150 mcg Tablets	
		Microgynon 30	Ethinylestradiol 30mcg & Levonorgestrel 150mcg Tablets	
		Microgynon ED 30	Ethinylestradiol 30mcg & Levonorgestrel 150mcg Tablets	
		Ovranette	Ethinylestradiol 30mcg & Levonorgestrel 150mcg Tablets	
		Trinovum	Ethinylestradiol 35mcg & Norethisterone 500, 750, 1000mcg Tablets	
		Yasmin	Ethinylestradiol 30mcg & Drospirenone 3mg Tablets	
		Evra patch	Ethinylestradiol & Norelgestromin Patches	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
7.3.2	Oral Progestogen-only Contraceptives			
7.3.2.1	Oral Progestogen-only Contraceptives			
		Cerazette, Desorex	Desogestrel 75mcg Tablets	
		Micronor, Noriday	Norethisterone 350mcg Tablets	
		Norgeston	Levonorgestrel 30mcg Tablets	
7.3.2.2	Parenteral Progestogen-only Contraceptives			
			Medroxyprogesterone 150mg in 1ml PFS R	
7.3.2.3	Intra-uterine Progestogen Only System			
			Levonorgestrol 52mg IU (Mirena) R	
7.3.3	Spermicidal contraceptives			
		Gygel	Nonoxinol 9 0.2% Gel	
7.3.4	Intra-uterine devices			
			Nova T 380	
			Flex T	
7.3.5	Emergency Contraceptives			
		Levonelle	Levonogrestrel 1500 mcg Tablets	FSRH Guidance: Emergency Contraception
			Ulipristal Tablets (ellaOne) SA	
7.4.1	Drugs for Urinary Retention			
		Alpha blockers		NICE CG97: The management of lower urinary tract symptoms in men, May 2010.
		1st line	Doxazosin Tablets (Standard release)	
		1st line	Tamsulosin Modified Release Capsules	
			Indoramin Tablets	
			Alfuzosin Tablets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
7.4.2	Drugs for urinary frequency, enuresis, and incontinence			.
		1st line	Oxybutynin immediate release Tablets	NICE TA290: Mirabegron for treating symptoms of overactive bladder. NICE 171: Urinary incontinence: the management of urinary incontinence in women NICE CG 40: Urinary incontinence in women, quick reference guide Oct 2006. NICE CG148: Urinary Incontinence in Neurological Disease. Antimuscarinic Treatment Pathway for the Management of Urinary Incontinence in Women. C&W APC Antimuscarinic Pathway for urinary Incontinence in Women.
		1st line	Tolterodine immediate release Tablets	
		2nd line	Tolterodine MR Capsules	
		2nd line	Trospium Chloride I/R Tablets	
		2nd line	Trospium Chloride M/R Capsules R	
		2nd line	Fesoterodine MR Tablets	
		2nd line	Solifenacin Tablets	
			Darifenacin 7.5 mg MR Tablets	
			Propiverine Tablets 15mg & Mr Capsules 30mg	
			Mirabegron Tablets SI	
			Botulinum Toxin Injection A SO (Not routinely commissioned for overactive bladder). See section BNF 4.9.3.	
			Botulinum Toxin Injection B SO (Not routinely commissioned for overactive bladder). See section BNF 4.9.3.	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
7.4.3	Drugs Used in Urological Pain			
			Sodium Bicarbonate Capsules, Tablets (Specialist)	
			Sodium Citrate 0.3M 30ml Mixture (Specialist)	
7.4.4	Bladder Instillations and Urological Surgery			
			Sodium Chloride 0.9% 1L,3L Irrigation	
			Urotainer Sodium Chloride	
			Glycine 1.5% Irrigation 3L	
			Urotainer Solution R	
7.4.5	Drugs for Erectile Dysfunction	PDE-5 Inhibitors*		
		1st line	Sildenafil Tablets (Specialist)	NICE Clinical Clinical Guideline CG66: Type 2 Diabetes Section 18.4 Erectile Dysfunction
		2nd line	Tadalafil 10mg/20mg Tablets (Specialist)	
			Alprostadil Inj 5mcg, Alprostadil Transurethral 250mcg Application	
<p>* PDE-5 Inhibitors except for generic sildenafil are not allowed on NHS prescription in primary care except under the terms of the selected list scheme as outlined in Part XVIII B of the Drug Tariff</p> <p>Discouraged list from APC. Tadalafil 2.5mg and 5mg (Daily dose), No efficacy benefit over PRN dosing, If NHS criteria met, prescribe sildenafil (on a "when necessary basis"). Maximum 4 tablets per month to be prescribed</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
<p>Please Note: Prescribing chemotherapy for cancer indications should only be prescribed by an authorised chemotherapy prescriber and with reference to the current MOSAIQ Formulary and network deviation policy.</p>				
				Dispensing guidelines for drugs and clinically checked by pharmacy team. - Blood levels, weights etc that need checking when dispensing certain drugs. NPSA Jan 2008 states dispensary staff should have access to information and need to check when dispensing. See BNF p 547.
8.1	Cytotoxic drugs			
			Dexrazoxane SO (Savene) IV Infusion	
			Calcium folinate (300mg/30ml) 30mL Vial	
			Calcium folinate (50mg/5ml) 5mL Vial	
			Mesna IV SO (Restrict to use with cyclophosphamide and isophosphamide and to oncology, haematology and rheumatology.	
8.2	Drugs affecting the immune response			
8.2.1	Antiproliferative Immunosuppressants			
			Azathioprine 25mg, 50mg Tablets SC	
			Mycophenolate mofetil Capsules 250mg, 500mg SC	
8.2.2	Corticosteroids and other immunosuppressants			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Ciclosporin (Neoral) Capsules 25mg, 50mg, 100mg, 100mg/ml Liquid R (Specialist)	
8.2.4	Other Immunomodulating Drugs			
			BCG - Medac Bladder Instillation (Specialist)	
			BCG (OncoTICE) 12.5 mg Bladder Instillation (Specialist)	
			BCG (ImmuCyst) 81 mg Bladder Instillation (Specialist)	
			Interferon alfa-2a (Roferon-a) and (Intron-a) (Specialist)	
			Interferon beta 1a SO (For Multiple Sclerosis Specialist)	
			Interferon beta 1b SO (For Multiple Sclerosis Specialist)	
			Peginterferon alpha 2a/ peginterferon alpha 2b SO R (Gastroenterologist only)	
8.3	Sex hormones and hormone antagonists in malignant disease			
8.3.1	Oestrogens			
			Diethylstilboestrol Tablets SA	
8.3.2	Progestogens			
			Megesterol Acetate Tablets 160mg (Specialist)	
8.3.3	Androgens			
8.3.4	Hormone antagonists			
8.3.4.1	Breast cancer			
			Anastrozole Tablets 1 mg Tablets SC	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Exemestane Tablets 25mg SC	
			Letrozole Tablets SC	
			Tamoxifen Tablets 10mg, 20mg	
8.3.4.2	Gonadorelin analogues and gonadotrophin-releasing hormone antagonists			
		Gonadorelin analogues		
			Goserelin Injection 3.6mg SI (Early and advanced breast cancer)	
			Goserelin Injection 3.6mg, 10.8mg SA (Prostrate cancer)	
			Leuprorelin 3.75mg, 11.25mg Injection 1 Pre-filled Syringe R (Specialist)	
		Anti-androgens		
			Bicalutamide Tablets SC R	
			Cyproterone Tablets SA (Specialist in urology and oncology)	
			Flutamide Tablets SC R (Specialist)	
8.3.4.3	Somatostatin analogues			
			Lanreotide Injection SO (neuroendocrine particularly carcinoid tumours and acromegaly)	
			Lanreotide Injection SO (Thyroid tumours)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Octreotide Injection SO (neuroendocrine (particularly carcinoid) tumours and acromegaly)	
			Octreotide injection SC (Indicated for - reduction of vomiting in palliative care)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
9.1	Anaemias and some other blood disorders			
9.1.1	Iron-deficiency Anaemias			
9.1.1.1	Oral Iron			
				NICE CG114: Anaemia management in chronic kidney disease (replaces CG39)
		1st line	Ferrous Sulphate 200mg Tablets	
		1st line	Ferrous Fumarate 210mg Tablets	
		2nd line	Ferrous Fumarate 140mg/5ml Syrup	
			Ferrous Fumarate 305mg Capsules	
			Ferrous Gluconate 300mg Tablets	
		Iron and Folic Acid		
			Sodium Feredetate (Sytron) 190mg/5ml Elixir	
9.1.1.2	Parenteral Iron			MHRA Drug Safety Update: Intravenous iron and closer monitoring
			Iron Sucrose 20mg/1ml Injection (Venofer)	
			Iron 100mg/1ml Injection (Monofer)	
9.1.2	Drugs used in Megaloblastic Anaemias			
			Hydroxocobalamin 1mg/1ml Injection	
			Cyanocobalamin 50mcg Tablets	
			Folic acid 2.5mg/5ml Syrup	
			Folic acid 400 mcg Tablets	
			Folic acid 5mg Tablets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
9.1.3	Drugs used in Hypoplastic, Haemolytic, and Renal Anaemias			MHRA - Erythropoietins (Dec 2007) haemoglobin conc 2007 and July 2008). Erythropoietins - tumour progression and survival in patients with cancer erythropoietins MHRA Dec Pure cell aplasia- don't switch to another form of NICE TA 142: Epoetin alfa, beta darbepoetin alfa for cancer treatment induced anaemia. May 2008
			Darbepoetin Alfa 40 mcg Pre-filled Syringe Darbepoetin Alfa 100 mcg Pre-filled Syringe Darbepoetin Alfa 300 mcg Pre-filled Syringe SO (In anaemia for patients receiving cytotoxics)	
			Darbepoetin Alfa 40 mcg Pre-filled Syringe Darbepoetin Alfa 100 mcg Pre-filled Syringe Darbepoetin Alfa 300 mcg Pre-filled Syringe SC (To be used in renal anaemia)	
			Epoetin Alfa and Beta SO (In anaemia for patients receiving cytotoxics)	
			Epoetin Alfa and Beta SC (To be used in renal anaemia)	
		Sickle Cell Disease	Hydroxycarbamide SO	
		Iron Overload		
			Deferasirox Dispersible Tablets SO (Haemotologists)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Desferrioxamine Mesylate 500mg, 2g Injection SO (Haematology)	
	Paroxysmal Nocturnal Haemoglobinuria and Atypical Haemolytic Uraemic Syndrome			
9.1.4	Drugs used in Platelet Disorders			
	Idiopathic Thrombocytopenic Purpura			
	Used in Essential Thrombocythaemia			
			Anagrelide 500mcg Capsules SO (Haematologists)	MHRA warning on cardiovascular risk - Jan 13
			Romiplostim 250mcg Injection R (Haematologists)	NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (April 2011) Direct Healthcare Professional Communication - September 2011
			Immunoglobulin R (As per National Demand Programme)	www.ivig.nhs.uk
9.1.6	Drugs used in Neutropenia			
			Filgrastim 300 mcg/0.5ml (30miu) PF Syringe, 480 mcg/0.8ml (48miu)PF Syringe SO	
			Lenograstim Injection 105 mcg, 262 mcg SO	
9.1.7	Drugs used to mobilise stem cells			
			Plerixafor 20mg/ml Injection R (To haematologist and patients that have failed with G-CSF mobilisation)	
9.2	Fluids and Electrolytes			
9.2.1	Oral Preparations for fluid and Electrolyte Imbalance			
9.2.1.1	Oral Potassium			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		Hypokalaemia		
			Potassium Chloride Effervescent Tablets 470mg, 12mmol K+ (Sando K)	
			Potassium Chloride Syrup 7.5%, 1mmol/ml K+ (Kay-Cee-L)	
		Hyperkalaemia		
			Calcium Polystyrene Sulphonate (Calcium Resonium Powder)	
9.2.1.2	Oral Sodium and Water			
		Hyponatremia		
			Oral Rehydration Salts (Dioralyte or Electrolade)	
9.2.1.3	Oral Bicarbonate			
		Chronic Acidotic States	Sodium Bicarbonate Capsules 500mg	
9.2.2	Parenteral preparations for fluid and electrolyte imbalance			
9.2.2.1	Electrolytes and Water			
		Sodium Chloride	Sodium Chloride 0.9% Injection (5ml, 10ml)	Update on the implementation of recommended safety controls for potassium chloride in the NHS in November 2003.
		Sodium Chloride & Glucose	Sodium Chloride 0.18%, + glucose 4% (500ml, 1L) IV Infusion	
			Sodium Chloride 0.18%, + glucose 10% (500ml) IV Infusion	
			Sodium Chloride 0.45%, + glucose 5% (500ml) IV Infusion	
			Sodium Chloride 0.9%, + glucose 5% (500ml) IV Infusion	
		Sodium Lactate	Sodium Lactate Compound (500ml, 1l) IV Infusion	
		Sodium Chloride	Sodium Chloride 0.9% inj (50ml, 100ml) bag IV Infusion	
			Sodium Chloride 0.9% (100ml, 250ml, 500ml, 1l) IV Infusion	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Sodium Chloride 0.45% IV Infusion 500mL	
		Glucose	Glucose 5% (100ml, 250ml, 500ml, 1l,) IV Infusion	
			Glucose 10% (500ml) IV Infusion	
			Glucose 20% (500ml) IV Infusion	
			Glucose 50% (500ml) IV Infusion	
			Glucose 50% Injection (50mL) Vial (not Mini jet)	
		Potassium Chloride and Glucose		
			Potassium 0.15% + Glucose 5% (500ml, 1l)) (20mmol K+/litre) IV Infusion R	
			Potassium 0.3% + Glucose 5% (1l) (40mmol K+/litre) IV Infusion	
		Sodium Bicarbonate		
			Sodium Bicarbonate 1.4%, IV Infusion	
			Sodium Bicarbonate 1.26%, IV Infusion	
			Sodium Bicarbonate 4.2%, IV Infusion	
			Sodium Bicarbonate 8.4% IV Infusion	
			Sodium Bicarbonate 8.4% Minijet	
		Potassium and Sodium chloride	Potassium 0.075% + Sodium Chloride 0.9% (10mmol K+/litre) IV Infusion	
			Potassium 0.15% + Sodium Chloride 0.9% (20mmol K+/litre) (500ml,1l) IV Infusion	
			Potassium 0.3% + Sodium Chloride 0.9% (40mmol K+/litre), (1l) IV Infusion	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Potassium 0.45% + Sodium Chloride 0.9% (60mmol K+/litre) (1l) IV Infusion R (Order in CD book)	For infusion ready-prepared solutions (which contain up to 40mmol/litre KCl) should normally be used. Solutions containing more than 40mmol/L potassium should be administered with ECG monitoring. NPSA:Update on the implementation of recommended safety controls for potassium chloride in the NHS. Nov 03.
			Potassium 0.6% + Sodium Chloride 0.9% (80mmol K+/litre), IV Infusion R (Order in CD book)	
			Potassium Chloride Strong 1.5g in 10mL Injection R (Order in CD book)	
		Water		
			Water for Injection 5ml, 10ml, 20ml, 50ml, 100ml	
			Water for Irrigation (1l)	
		Glucose Nacl KCl		
			Glucose 4% + Sodium Chloride 0.18% Potassium 0.15% (1L) (20mmol K+/litre) IV Infusion	
		Glucose 4%/5%, NaCl 0.18%, 0.45%, 0.9%		
			Glucose 4% + Sodium Chloride 0.18% (500ml) IV Infusion	
			Glucose 5% + Sodium Chloride 0.45% (500ml) IV Infusion	
9.2.2.2	Plasma and Plasma Substitutes			
			Gelaspan	MHRA suspends use of hydroxyethyl starch (HES) infusions (June 13).

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
9.4	Oral Nutrition		Hydroxyethyl start 6% balanced isotonic solution R (With advice from nutritional team)	C&W APC Sip Feeds - Guidelines: MUST tool Sip Feeds - Patient leaflet C&W APC Sip Feeds - Ways to boost food intake Feeds - Prescribing policy C&W APC Sip Feeds - Consider Sip Feeds NICE CG32: Nutrition support in adults
9.4.1	Foods for Special Diets			C&WAPC
9.4.2	Enteral nutrition			C&WAPC Sip
			Nutramigen Lipil stage 2 Powder	
			Carobel	
			Fortijuice	
			Fortini	
			Fortisip	
			Fortisip compact	
			Fortisip compact fibre	
			Fortisip multifibre	
			Fortisip extra	
			Fortisip yoghurt	
			Maxijul super soluble Powder	
			Nutilis	
9.5	Minerals			
9.5.1	Calcium and Magnesium			
9.5.1.1	Calcium Supplements			
		Hypocalcaemia	Adcal Tablets	
			Adcal D3 Tablets	
			Sandocal 1000 Tablets	
			Calcium Gluconate (5ml, 10ml) 10% Injection	
			Calcium Chloride 10% Pre-filled Syringe	
9.5.1.2	Hypercalcaemia and Hypercalciuria			
			Disodium Pamidronate Injection 30mg. 90mg	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Calcitonin Injection (See BNF 6.6.1)	
			Cinacalcet Tablets SC	NICE TA117: Hyperparathyroidism - cinacalcet
9.5.1.3	Magnesium			
			Magnesium Glycerophosphate Tablets	
			Magnesium Sulphate 50% Injection (2ML, 10ML)	
			Magnesium Sulphate 10% Injection (10ml)	
9.5.2	Phosphorus			
9.5.2.1	Phosphate Supplements			
			Phosphate Sandoz Soluble Tablets	
9.5.2.2	Phosphate Binding Agents			
9.5.4	Zinc			
			Zinc sulphate (Solvazinc) 125mg Effervescent Tablets R (In proven deficiency)	
9.5.5	Selenium			
9.6	Vitamins			
9.6.1	Vitamin A			
9.6.2	Vitamin B			
			Thiamine Tablets 50mg, 100mg	
			Vitamins B+C Strong IV (Pabrinex® IV) Injection	
			Pyridoxine Tablets 10mg (Unlicensed) R (In some deficiency, seizure cases)	
			Pyridoxine Tablets 50mg	
			Vitamin B Compound Strong Tablets	
			Hydroxocobalamin Injection (See BNF section 09.01.02)	
9.6.3	Vitamin C			
			Ascorbic Acid 50mg, 100mg, 500mg, Chewable Tablets 500mg	
9.6.4	Vitamin D			
			Calcium and Ergocalciferol Tablets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Ergocalciferol 1500 units in 1ml Solution	C&W APC High Potency Vitamin D replacement in Patients with Vitamin D deficiency or insufficiency. May 2013. C&W APC Vitamin D - National Osteoporosis guidelines used in SWFT. Guidelines:brief prescribing
			Colecalciferol 800 iu Capsules	
			Ergocalciferol Liquid 20,000 units/ml Oral Suspension SO (Unlicensed)	
			Ergocalciferol Injection 300,000 units/1ml (Licensed)	
			Ergocalciferol Injection 600,000 units/1.5ml	
			Alfacalcidol Capsules 250, 500 nanograms, 1mcg	
			Alfacalcidol Drops (2 micrograms/ml, 10ml 1 drop = 100 nanograms)	
			Calcitriol (Rocaltrol) 250 nanograms Capsules	
			Adcal D3, Tablets, Effervescent Tablets, Lemon Tablets	NICE TA 160: Osteoporosis primary prevention
			Calceos Tablets	NICE TA 161: Osteoporosis secondary prevention
9.6.6	Vitamin K			
			Phytomenadione Injection (Konakion MM®) 10mg/ml	
			Phytomenadione Injection (Konakion MM® Paediatric) 2mg/0.2ml	
9.6.7	Multivitamin preparations			
			Forceval Capsules	
			Forceval Junior Capsules	
			Abidec Drops	
			Multivitamins Tablets	
			Vitamin co (Dalivit Drops) 25ml	
9.8.2	Acute Porphyrias			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
<p><u>Discouraged list</u> Modified Release iron preparations (Feospan[®], Ferrograd[®], Fefol[®], Ferrograd folic[®], Ferrograd C[®]). No therapeutic advantage, lower iron absorption. Prescribe ferrous fumarate (or ferrous sulphate/ferrous gluconate if intolerance to ferrous fumarate). Fluoride products- tablets, mouthwashes, toothpastes, gels, oral drops (En-De-Kay[®], Fluor-a-day[®], FluoriGard[®], Duraphat[®]) . If appropriate these should be prescribed by dentists. Vitamin B Compound. No clear place in therapy for any condition. (Ref APC). If a vitamin B complex preparation is needed (e.g. in alcoholism), Vitamin B Compound Strong tablets can be prescribed. Co-agulation tests. Coagucheck PT[®], Coagucheck XS PT[®] (INR monitoring contracted and testing by patients not approved due to concerns about equipment maintenance). Refer patient to anticoagulant clinic for monitoring by a healthcare professional, unless prescriber is assured of arrangements for appropriate quality control of meter. Eltrombopag - NICE TA 205 not recommended. BNF section A2.5.1 Special additives for conditions of intolerance- Colief[®]- Only allowed on the NHS under strict criteria in which the patient, an infant, would need a specialised diagnostic test - Specialist use only. VSL#3 powder sachets- Lack of evidence for indications other than Ileoanal Pouchitis that has been induced by antibiotics.</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
10				
10.1	Drugs in Rheumatic Diseases and Gout			
10.1.1	NSAIDs	NSAIDs		
				MeReC Extra Issue No. 30: Cardiovascular and gastrointestinal safety of NSAIDs Nov 2007
				MeReC Rapid Review: Even more data on cardiovascular risks of NSAIDs: time to review prescribing Oct 2011
				MeReC Rapid Review: NSAIDs and cardiovascular risks – more evidence, but this shouldn't be new news Feb 2011
				MHRA Advice: Diclofenac: new contraindications and warnings after a Europe-wide review of cardiovascular safety Jun 2013
				MHRA Advice: Non-steroidal anti-inflammatory drugs (NSAIDs): further evidence that the cardiovascular risk with diclofenac is higher than other non-selective NSAIDs and similar to the selective COX-2 inhibitors Oct 12.
				NICE CG 59: Osteoarthritis Feb 2008
				NICE CG 79: Rheumatoid Arthritis Feb 2009
				NICE CG 88: Low Back Pain May 2009
				CHMP advice. Piroxicam Jun 2007
		1st line	1) Ibuprofen Tablets, Suspension	
		1st line	2) Naproxen Tablets	
			3) Mefenamic acid Capsules, Suspension R (Restricted for period pain only)	
			4) Meloxicam Tablets R (Restricted for morning stiffness)	
			5) Etoricoxib R (If intolerant to NSAID + PPI)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			6) Diclofenac Tablets, Capsules, Suppositories, Injection R (For short term use and no CV risk)	
10.1.2	Corticosteroids			
10.1.2.1	Systemic Corticosteroids			
			Prednisolone Tablets	
10.1.2.2	Local Corticosteroid Injections			
			1)Hydrocortisone acetate SO	
			2)Methylprednisolone acetate 40mg/ml Aq suspension (Intra-articular) SO	
			3)Triamcinolone 40mg/ml Aq Suspension (Intra-articular) SO	
10.1.3	Drugs that suppress the rheumatic disease process			
		DMARD		
		Gold	Sodium Aurothiomalate Injection I/M SC	
			Hydroxychloroquine Tablets SC	
			Azathioprine Tablets SC (Also see BNF section 8.2.1)	
			Ciclosporin Capsules SC (Also see BNF section 8.2.2)	
			Leflunomide Tablets (Hospital use only) SC	
			Methotrexate Tablets (PBR exclusion) SC	NPSA Safety Alert 13: Oral methotrexate. Improving compliance with oral methotrexate guidelines Jun 2006
			Methotrexate Injection 50mg/ml sc (Metaject) SC	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		Cytokine modulators (Specialist)		NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor Aug 2010 NICE TA130: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis Oct 2007
			Adalimumab Injection SO (Restrict to rheumatology, Gastro intestinal, Dermatology, Juvenile Idiopathic Arthritis)	TA143:Adalimumab, etanercept and infliximab for ankylosing spondylitis May 2008
			Certolizumab Injection SO	NICE TA186: Certolizumab pegol for the treatment of rheumatoid arthritis Feb 10
			Etanercept Injection SO (Rheumatology, dermatology, juvenile idiopathic arthritis)	NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Aug 2010
			Infliximab IV Infusion SO (Rheumatology, gastroenterology, dermatology, juvenile idiopathic arthritis)	
			Infliximab IV Infusion with Methotrexate SO (Rheumatology)	
			Rituximab IV Infusion SO R (Rheumatology, Haematology, Juvenile Idiopathic Arthritis)	NICE 195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor Aug 10.
			Abatacept IV Infusion with Methotrexate SO (Rheumatology, and with Juvenile Idiopathic Arthritis)	NICE TA280; Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234) Apr 2013 NICE TA 195 : Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor Aug 10.
			Sulfasalazine Tablets SC	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Tocilizumab IV Infusion SO R (Rheumatology, Systemic Juvenile Idiopathic Arthritis)	NICE TA 247 : Tocilizumab for the treatment of rheumatoid arthritis Feb12
			Golimumab Injection SO (Rheumatology)	NICE TA233: Golimumab for the treatment of ankylosing spondylitis (Aug 2011). NICE TA220: Golimumab for the treatment of psoriatic arthritis (Apr 2011) NICE TA225: Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab - (Jun 2011) NICE TA 225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
10.1.4	Gout and cytotoxic induced hyperuricaemia			
	Acute gout			
			1) Naproxen Tablets	
			2) Etoricoxib Tablets	
			3) Colchicine Tablets	
	Long term control of gout			
		1st line	Allopurinol Tablets	
		2nd line	Febuxostat Tablets	NICE TA 164: Febuxostat for the management of hyperuricaemia in patients with gout (Dec 2008).
			Rasburicase IV Infusion SO (Haematology)	
10.2.2	Skeletal muscle relaxants			
			Baclofen Tablets SA	
			Dantrolene Capsules SA	
			Diazepam Tablets	
			Tizanidine Tablets SC	
10.3	Drugs for the treatment of soft tissue disorders and topical pain relief			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
10.3.1	Enzymes		Hyaluronidase Injection (Restricted)	
10.3.2	Rubefaciants, topical NSAIDs, capsacin, poultices			
		1st line	Ibuprofen Gel	
		2nd line	Diclofenac Gel R (Pain team, rheumatology)	
			Capsaicin 0.025% Cream SO	
			MoveLat Cream, Gel	
			Piroxicam Gel	
			Algesal Cream	
<p><u>C & W APC discouraged list</u> - Cannabis sativa extract (Sativex®) (not recommended by NICE/APC), Ketoprofen with Omeprazole (Axorid®), Naproxen with Esomeprazole (Vimovo®) , Diclofenac potassium/retard (Voltarol® Rapid and Voltarol Retard®), Hylan G-F 20 (not recommended by NICE/APC), (Synvisc®, Synvisc One®). Sodium hyaluronate (not recommended by NICE/APC).</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
11				
11.1	Administration of drugs to the eye	No drugs		
11.2	Control of microbial contamination	No drugs		
11.3	Anti-infective eye preparations			
11.3.1	Antibacterials			
			Chloramphenicol Eye Drops 0.5%, Eye Ointment 1%	
			Ciprofloxacin Eye Drops 0.3%	
			Fusidic Acid Eye Drops 1%	
			Gentamicin Eye Drops 0.3%	
			Ofloxacin Eye Drops 0.3%	
11.3.3	Antivirals			
			Aciclovir Eye Ointment 3%	
			Ganciclovir R (Specialist)	
11.4	Corticosteroids and other anti-inflammatory preparations			
11.4.1	Corticosteroids			
			Betamethasone Eye Drops 0.1%	
			Dexamethasone (Maxidex) Eye Drops, Minims 0.1%	
			Dexamethasone 0.1%, Neomycin, Polymyxin (Maxitrol) Drops and Ointment	
			Fluorometholone (FML) Eye Drops 0.1%	
			Prednisolone Eye Drops 0.5%, 1%	
			Rimexolone (Vexol) Eye Drops 1%	
			Dexamethasone 700 micrograms Intravitreal Implant R (Specialist)	NICE TA 229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion.
11.4.2	Other anti-inflammatory preparations			
			Sodium Cromoglicate Eye Drops 2%, Ophthalmic Unit Doses, Drops	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
11.5	Mydriatics and Cycloplegics			
			Atropine Eye 1.0% Drops, Minims	
			Cyclopentolate Eye 0.5%, 1% Drops, Minims	
			Tropicamide 0.5%, 1% Eye Drops, Minims	
			Phenylephrine 2.5%, 10% Minims.	
	Antimuscarinics			
11.6	Treatment of Glaucoma			NICE CG 85: Glaucoma - diagnosis and management of chronic open angle glaucoma and ocular hypertension 2009.
		Beta Blocker		
			Betaxolol Eye Suspension Drops 0.25% SA	
			Betaxolol Eye Solution 0.5% SA	
			Timolol 0.25%, 0.5% Eye Drops, Ophthalmic Unit doses, LA Gel SA	
			Levobunolol 0.5% Eye Drops, Ophthalmic Unit Doses SA	
			Carteolol 1%, 2% Eye Drops SA	
		Prostaglandin Analogues		
			Bimatoprost 100 mcg/ml Drops SA	
			Bimatoprost 300 mcg/ml Drops SA	
			Bimatoprost 300mcg/ml, Timolol 5mg/ml (Ganfort Drops) SA	
			Latanoprost 50mcg/ml Drops SA	
			Latanoprost 50 mcg, Timolol 5 mg/ml (Xalacom) Drops SA	
			Travoprost Eye Drops 40 mcg/ml SA (Travatan)	
			Travoprost 40 mcg/ml, Timolol 5 mg/ml Eye Drops (Duotrav) SA	
			Tafluprost 15mcg/ml SA (Saflutan)	
		Sympathomimetics		
			Brimonidine Eye Drops 0.2% SA	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Brimonidine Eye Drops 0.2%, Timolol 0.5% Eye Drops SA (Combigan)	
		CA Inhibitors		
			Dorzolamide Eye Drops 2% SA	
			Dorzolamide Ophthalmic Unit Doses 2% SA	
			Dorzolamide 2%, Timolol 0.5% Eye Drops SA (Cosopt)	
			Dorzolamide 2%, Timolol 0.5% Ophthalmic Unit Dose SA (Cosopt)	
			Brinzolamide Eye Drops 10mg/ml	
			Brinzolamide 10mg/ml, Timolol 5mg/ml Eye Drops	
		Miotics		
			Pilocarpine Eye Drops 2%, 4% SA	
			Pilocarpine 2%, Minims SA	
			Acetazolamide Tablets 250mg, SR Capsules, 500mg Injection	
11.7	Local Anaesthetics			
			Lidocaine hydrochloride 4%, Fluorescein Sodium 0.25% Minims	
			Oxybuprocaine Minims (benoxinate) 0.4%	
			Proxymetacaine 0.5% Minims	
			Proxymetacaine and Fluorescein Minims	
			Tetracaine Eye Drops 1%	
11.8	Miscellaneous ophthalmic preparations			
11.8.1	Tear deficiency, ocular lubricants and astringents			
		Hypromellose /Acetylcysteine		
			Acetylcysteine 5%, Hypromellose 0.35% Eye Drops	
		Carbomers		

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Gel Tears 0.2% Gel	
			Viscotears 0.2% Gel	
			Viscotears 0.2% Single Dose Units	
			Liquivisc 0.25% Gel	
		Carmellose		
			Carmellose 0.5%, 1.0% Ophthalmic Unit Dose 30, 90	
		Hypromellose		
			Hypromellose Eye 0.3% Drops, Ophthalmic Unit Dose	
			Hypromellose Eye Drops 1%	
			Hydroxyethylcellulose Eye Drops 0.44%, Sodium Chloride 0.35% (Artificial Tears Minims)	
			Hypromellose Eye Drops 0.3%, Dextran '70' 0.1% Tears Naturale	
		Paraffin		
			White Soft Paraffin 57.3%, Liquid Paraffin 42.5% Eye Ointment (Lacrilube)	
			Liquid Paraffin 10%, Wool Fat 10%, Yellow Soft Paraffin Eye Ointment (Simple Eye Ointment)	
		Poly vinyl		
			Polyvinyl Alcohol Eye Drops, Minims 1.4% (Liquifilm)	
			Polyvinyl Alcohol Eye Drops 1.4% (Sno-tears)	
		Sodium Chloride 0.9%		
			Sodium Chloride 0.9% (Minims)	
			Sodium Chloride 5.0% Drops R (Specialist)	
			Sodium Chloride 5.0% PF Drops R (Specialist)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
11.8.2	Ocular diagnostic and peri-operative preps and photodynamic			
	Ocular diagnostic preparations			
		Fluorescein		
			Fluorescein 1% (Minims)	
			Fluorescein 20% Injection (Unlicensed)	
	Ocular peri-operative drugs			
			Acetylcholine 1% Intra-ocular Solution R (Specialist)	
			Apraclonidine 0.5% Solution SO	
			Diclofenac 0.1% Ophthalmic Unit Dose	
			Ketorolac Trometamol Eye Drops 0.5%	
		Sodium Hyaluronate		
			Sodium Hyaluronate 8.5mg in 0.85ml PF Syringe R (Specialist)	
			Sodium Hyaluronate GV 7.7mg in 0.55ml Injection R (Specialist)	
			Disod Edetate 0.37% Solution R (Specialist)	
			Balanced Salt Solution 19ml	
			Balanced Salt Solution 500ml	
			Trifluorothymidine (F3T) 1% Eye Drops (Unlicensed) R (Specialist)	
	Sub foveal Choroidal Neovascularisation			
			Ranibizumab (Lucentis) Intravitreal Injection SO	NICE TA155: Macular degeneration (age-related) - ranibizumab and pegaptanib NICE TA 237: Ranibizumab for the treatment of diabetic macular oedema NICE TA 68: Verteporfin photodynamic therapy for wet age related macular degeneration.

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
11.9	Contact Lenses			
<p><u>Discouraged list.</u> hypromellose single unit eye Drops (pf) Artelac SDU, Eye lid wipes/scrubs Blephaclean, Blephasol, Lid care, Ocusoft. Pegaptanib Not recommended NICE TA 237. Macushield.</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
12.1	Drugs acting on the ear			
12.1.1	Otitis Externa			
			Aluminium Acetate 8% Ear Drops R (Specialist)	
			Betamethasone Ear Drops 0.1%	
			Betamethasone Ear Drops 0.1% Neomycin 0.5%	
			Dexamethasone 0.1 %, Neomycin, Glacial Acetic Acid 2% Ear Spray (Otomize)	
			Dexamethasone 0.05%, Framycetin Sulfate 0.5% and Gramicidin 0.05% Ear Drops (Sofradex)	
			Flumetasone Pivalate and, Clioquinol Ear Drops (Locorten-Vioform).	
			Hydrocortisone and Gentamicin Ear Drops (Gentisone HC)	
			Hydrocortisone 1%, Neomycin 3400 units, Polymyxin (Otosporin Ear Drops) R (Specialist)	
			Prednisolone Sodium Phosphate 0.5% Drops	
			Chloramphenicol Ear Drops 5% R (Specialist)	
			Clotrimazole Solution 1%	
			Gentamicin 0.3% Drops	
12.1.2	Otitis Media			
12.1.3	Removal of earwax			
			Olive Oil	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Olive Spray	
			Sodium Bicarbonate Ear Drops	
			Earcalm Acetic Acid 2% Spray	
12.2	Drugs acting on the Nose			
12.2..1	Drugs used in Nasal Allergy			
			Azelastine 140 mcg Nasal Spray	
		Corticosteroids		
			Beclometasone Aqueous Nasal Spray 50mcg	
			Budesonide Nasal Spray (Rhinocort)	
			Betamethasone Sodium Phosphate 0.1% Drops	
			Fluticasone Nasal Spray 50 micrograms/dose	
			Fluticasone 400mcg in 0.4ml Nasules	
			Mometasone 50micrograms Nasal Spray	
			Sodium Cromoglicate Nasal Spray 4%	
			Fluticasone 27mcg Nasal Spray	
12.2.2	Topical Nasal Decongestants			
			Sodium Chloride 0.9% Nasal Minims	
			Ephedrine Nasal Drops 0.5%,	
			Xylometazoline Nasal Drops 0.1%	
			Xylometazoline Nasal Spray 0.1%	
			Xylometazoline Paediatric Nasal Drops 0.05%	
			Otrivine Menthol Nasal Spray	
12.2.3	Nasal preparations for Infection and Epistaxis			
			Mupirocin Nasal Ointment 2%	
			Naseptin Nasal Cream	
12.3	Drugs acting on the Oropharynx			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
12.3.1	Drugs for Oral Ulceration and Inflammation			
			Benzydamine 0.15% Oral Rinse	
			Benzydamine 0.15% Oral Spray	
			Hydrocortisone Mucoadhesive Buccal Tablets 2.5mg	
			Betamethasone 500mcg Soluble Tablets	
			Choline Salicylate Dental Gel	
12.3.2	Oropharyngeal Anti-Infective Drugs			
			Miconazole Oral Gel 2%	
			Nystatin Suspension 100,000 units/ml	
12.3.3	Lozenges and Sprays			
12.3.4	Mouthwashes, Gargles and Dentifrices			
			Chlorhexidine Mouthwash 0.2%, 300ml R (Restricted to prevention of mucositis and aphthous ulcers in patients receiving chemotherapy).	
			Chlorhexidine 1% Dental Gel	
			Hydrogen Peroxide 10 vol 3% Solution	
			Mouthwash Tablets	
12.3.5	Treatment of Dry Mouth			
			Biotene Oral Balance Gel	
			Glandosane Spray	
<p><u>Discouraged List</u> Compound preps for ear wax removal OTC, (Cerumol[®], Exterol[®], Molcer[®], Otex[®], Waxsol[®], Earex[®]), Organic solvents can cause irritation, Prescribe olive oil or sodium bicarbonate ear drops to soften wax. Other products can be purchased by patients from chemists if desired. Cosodyl Mouthwash (chlorhexidine) except for prevention of mucositis and aphthous ulcers in patients receiving chemotherapy.</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
13.1	Vehicles			
13.2	Emollient and Barrier preparations			NPSA alert. Fire hazard with paraffin-based skin products.
13.2.1	Emollients			
			Emulsifying Ointment BP	
			Paraffin, Yellow Soft	
			Liquid Paraffin and White Soft Paraffin Ointment 50:50	
			Aveeno Cream 100ml	
			Aveeno Cream 300ml Pump	
			Aveeno Lotion 500ml	
			Cetraben Cream Pump	
			Diprobase Cream	
			Diprobase Ointment	
			Doublebase 500g Gel	
			E 45 Cream	
			E 45 Lotion	
			E 45 Wash	
			Epaderm Ointment	
			Hydromol Cream 500g	
			Hydromol Ointment 125g/500g	
			Hydromol Bath/Shower Emollient	
			Oilatum Cream 40g, 150g	
			Balneum Plus Cream	
			Eucerin 5% Cream	
			Eucerin 10% Lotion	
			Eucerin 10% Cream	
			Dermol Cream	
			Dermol 500 Lotion	
			Balneum Cream	
			Balneum Plus Cream	
			Balneum Plus Bath Additive 500ml	
			Ungmentum Merck	
13.2.1.1	Emollient Bath and Shower preparations			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
	Bath/Shower			
			Aqueous Cream BP	
			Aveeno Bath Oil	
			Balneum Bath Additive 500ml	
			Balneum Plus Bath Oil	
			Oilatum Emollient 250ml	
			Oilatum Junior	
			Oilatum Pump Pack Cream 500ml	
			Dermol 600 Bath Additive	
			Dermol 200 Shower Emollient	
13.2.2	Barrier preparations			NICE CG 57: Atopic eczema in children
			Metanium Ointment	
			Sudocrem Cream	
			Conotrane Cream	
			Drapolene Cream	
13.3	Topical Local Anaesthetics and Antipruritics			NICE CG 57: Atopic eczema in children
			Calamine BP Lotion	
			Calamine Aqueous Cream	
			Crotamiton 10% Cream	
			Menthol 1.0% in Aqueous Cream	
			Menthol 2.0% in Aqueous Cream	
13.4	Topical Corticosteroids			NICE TA 81: Frequency of application of topical corticosteroids for atopic eczema
		Mild		
			Hydrocortisone Cream/ Ointment 0.5%, 1.0%, 2.5%	
			Hydrocortisone Cream 0.1%, (Dioderm)	
			Fluocinolone 0.025% Cream (Synalar 1 in 10)	
		Mild with Antimicrobials		

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Hydrocortisone 1%, Clotrimazole 1% Cream (Canesten HC)	
			Hydrocortisone 1%, Miconazole 2% Cream, Ointment (Daktacort)	
			Hydrocortisone 0.5%, Nystatin, Chlorhexidine 1% Cream (Nystaform HC)	
			Hydrocortisone 0.5%, Nystatin, Benzalkonium, Dimethicone Cream (Timodine)	
			Hydrocortisone 1%, Fusidic Acid 2% Cream, Ointment (Fucidin H)	
		Moderate		
			Betamethasone Valerate 0.025% Cream, Ointment (Betnovate RD)	
			Clobetasone Cream, Ointment (Eumovate)	
			Fludrocortide Cream, Ointment (Haelan)	
			Alclometasone Dipropionate 0.05% Cream (Modrasone)	
			Fluocinolone 0.00625% Cream, Ointment (Synalar 1 in 4)	
		Moderate with Antimicrobials		
			Clobetasone 0.05%, Oxytetracycline, Nystatin (Trimovate)	
		Moderate with Urea		
			Hydrocortisone 1%, Urea 10% Cream (Hydromol HC Intensive)	
		Potent		

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Betamethasone Valerate 0.1% Cream, Ointment , Scalp Lotion, (Betnovate) Foam (Bettamousse)	
			Fluocinonide 0.05% Ointment (Metosyn)	
			Fluticasone 0.05% Cream, Ointment (Cutivate)	
			Hydrocortisone Butyrate 0.1% Cream (Locoid)	
			Mometasone Furoate 0.1% Cream, Ointment, Scalp Lotion (Elocon)	
			Fluocinolone Acetonide 0.025% Cream, Ointment, Gel (Synalar)	
		Potent with Antimicrobials		
			Betamethasone and Clioquinol Cream (Betnovate C)	
			Betamethasone and Neomycin (Betnovate N) Cream, Ointment	
			Betamethasone Valerate 0.1%, Fusidic Acid 2% Cream (Fucibet)	
			Betamethasone Dipropionate 0.064%, Clotrimazole 1% Cream (Lotriderm)	
			Fluocinolone Acetonide 0.025% Clioquinol 3% Ointment (Synalar C)	
			Fluocinolone Acetonide 0.025% Neomycin 0.5% Cream (Synalar N)	
		Potent with Salicylic Acid		
			Betamethasone 0.05%, Salicylic Acid 3% (Diprosalic Ointment)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		Very potent		
			Clobetasol Propionate 0.05% Scalp Foam (Clarelux)	
			Clobetasol Propionate 0.05% Cream, Ointment (Dermovate)	
			Clobetasol Propionate 0.05% Shampoo (Etrivex)	
		Very potent with antimicrobials		
			Clobetasol with Neomycin and Nystatin Cream, Ointment	
13.5.1	Preparations for Eczema			
			Alitretinoin Capsules SO	NICE TAG 177 :Alitretinoin for the treatment of severe chronic hand eczema
13.5.2	Preparations for Psoriasis			NICE CG153:Psoriasis and psoriatic arthritis SIGN Oct 2010
		Vitamin D and Analogues		
			Calcipotriol Ointment, Scalp Application 50 micrograms/g (Dovonex)	
			Calcipotriol Betamethasone 0.05% Ointment, Gel 50 micrograms/g (Dovobet)	
			Tacalcitol 4mcg/g Lotion, Ointment (Curatoderm)	
		Tazarotene		
			Tazarotene 0.05% Gel (Zorac)	
		Tars		
			Coal Tar Solution 5% (Exorex)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Coal Tar Solution 12%, Salicylic Acid 2%, Prep Sulfur 4%, Coconut Oil Emollient (Sebco Ointment)	
		Dithranol		
			Dithranol Cream 0.25%, 0.5%, 1%, 2% R (To Dermatologist)	
		Oral Retinoids		
			Acitretin Capsules (Neotigason) SO	
13.5.3	Drugs affecting the Immune response			
			Azathioprine Tablets SC	
			Etanercept SO	NICE TA123:Etanercept and efalizumab for plaque psoriasis in adults July 2006.
			Methotrexate SC	NPSA Safety Alert 13: Oral methotrexate. Improving compliance with oral methotrexate guidelines Jun 2006.
			Methotrexate SC	
			Pimecrolimus 1% Cream SA	C&W APC. Pimecrolimus cream and tacrolimus ointment - Guidelines:for atopic dermatitis Sept 2009. NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
			Tacrolimus 0.03%, 0.1% Ointment SA	C&W APC. Pimecrolimus cream and tacrolimus ointment - Guidelines:for atopic dermatitis Sept 2009. C&W APC Tacrolimus/Ciclosporin - Urgent bulletin:branded only Jan 10. MHRA Advice: Tacrolimus ointment (Protopic): reminder of a possible risk of malignancies including lymphomas and skin cancers. NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) Astellas communication: Appropriate use of Protopic (tacrolimus) ointment to minimise risk
			Ciclosporin Capsules R (To Dermatologists when used with tacrolimus)	C&W APC Tacrolimus/Ciclosporin - Urgent bulletin:branded only Jan 10

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
13.6	Acne and Rosacea			
13.6.1	Topical preparations for Acne			
	Benzoyl Peroxide and Azelaic Acid			
			Azelaic Acid 15% Gel (Finacea)	
			Benzoyl Peroxide 3%, Clindamycin 1% (Duac)	
	Topical Antibacterials for Acne			
			Clindamycin Aq 1% Lotion	
			Clindamycin Aq Topical 1% Solution	
			Erythromycin 4% Solution 30ml, 90ml	
	Topical Retinoids and related preparations for Acne.			
			Adapalene 0.1% Cream, Gel	
			Adapalene 0.1% with Benzoyl Peroxide 2.5% Gel	
			Isotretinoin 0.05% Gel	
			Tretinoin 0.025% and Clindamycin 1% Gel	
	Other topical preparations for Acne.			
13.6.2	Oral preparations for Acne			
			Co-Cyprindiol Tablets	
			Isotretinoin 5mg, 20mg Capsules (Oral) SO	
13.7	Preparations for Warts and Calluses			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Glutaraldehyde 10% Solution	
			Podophyllotoxin 0.5% Solution, 0.15% Cream (Warticon)	
			Salicylic Acid Preparations (Occlusal, Salactol, Salatac, Verrugon, Cuplex)	
	Anogenital Warts			
			Imiquimod 5% Cream SO	
13.8	Sunscreens and Camouflagers			
13.8.1	Sunscreen preparations			
			Fluorouracil 0.5%, Salicylic 10% Acid Solution (Actikerall®) SO	
			Fluorouracil 5% Cream (Efudix) SO	
			Ingenol Mebutate Gel (Picato®) SO	
			Methyl-5-aminolevulinate (Metfix) SO R (To Dermatologists/ Oncologists)	
13.9	Shampoos and other preparations for scalp and hair conditions			
			Capasal Shampoo	
			Ceanal Conc Shampoo	
			Dermax Shampoo	
			T-Gel 2% Shampoo	
			Alphosyl 2 in 1 Shampoo	
			Ketoconazole 2% Shampoo	
			Cetrimide 10%, Undececenoic Acid 1% (Ceanel)	
13.10	Anti-infective skin preparations			
13.10.1	Antibacterial preparations			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
13.10.1.1	Antibacterial preparations only used topically			
			Mupirocin 2% Ointment, Cream	
			Mupirocin 2% Nasal Ointment	
			Silver Sulphadiazine 1% Cream	
			Polyfax Ointment	
13.10.1.2	Antibacterial preparations also used systemically			
			Fusidic acid 2% Ointment, Cream	
			Metronidazole 0.75% Gel (Anabact)	
			Metronidazole 0.75% Gel (Metrogel)	
			Metronidazole 0.75% Cream (Rozex)	
13.10.2	Antifungal preparations			
			Amorolfine Nail Lacquer 5%	
			Clotrimazole Cream 1% and 2%	
			Clotrimazole 1% Solution	
			Clotrimazole 1% Spray	
			Ketoconazole 2% Shampoo	
			Miconazole Cream 2%	
			Terbinafine Cream 1%	
			Nystaform Cream	
13.10.3	Antiviral preparations			
			Aciclovir Cream 5%	
13.10.4	Parasiticial preparations			
			Malathion Aqueous Solution 0.5%	
			Permethrin Lotion, Cream	
13.10.5	Preparations for minor cuts and abrasions			
			Proflavine Cream	
13.11	Skin cleansers, antiseptics, and desloughing agents			
13.11.1	Alcohols and saline			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
13.11.2	Chlorhexidine salts			
			Chlorhexidine 4% Scrub	
			Chlorhexidine 0.5% in IMS	
			Chlorhexidine Gluconate 150ml	
			Chlorhexidine Obstetric 1% Cream	
13.11.4	Iodine			
			Povidone Iodine 10% Alcoholic Solution	
			Povidone Iodine 10% Antiseptic Solution	
			Povidone Iodine 7.5% Surgical Scrub	
			Sodium Hypochlorite 1%	
13.11.6	Oxidisers and dyes			
			Hydrogen Peroxide 10 Vol 3% Solution	
			Potassium Permanganate 400mg Solution Tablets (Permitabs)	
13.11.7	Preparations for promotion of wound healing			
			Sterile Larvae (Maggots) (LarvE®) R (To wound nurses/consultants)	
13.12	Antiperspirants			
			Aluminium Chloride Hexahydrate 20% in Alcoholic Base (Driclor®)	
<p><u>Discouraged List</u> Tioconazole cutaneous solution (Trosyl), Eflornithine (Vaniqua), Topical antihistamines (Eurax, Anthisan, Histergan), Silicone Gels or Sprays</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
<p>Please refer to the 'Immunisation Against Infectious Disease' Department of Health Green Book, which has the latest information on vaccines and vaccination procedures for all the vaccine preventable infectious diseases that may occur in the UK. Recommended immunisation schedules can be found in the BNF.</p>				

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
15.1				
15.1.1	Intravenous Anaesthetics			
			Ketamine Injection 10mg/ml, 20ml, 50ml CD	
			Propofol Injection 1% (1g in 100ml) 20ml, 100ml	
			Propofol Injection 2% (2g in 100ml) 50ml	
			Thiopental Sodium 500mg Vial	
15.1.2	Inhalational Anaesthetics			
			Isoflurane Liquid	
			Sevoflurane Liquid	
15.1.3	Antimuscarinic drugs			West Midlands Palliative Care Guidelines. Liverpool Care Pathway.
			Atropine Injection 600 micrograms/ml	
			Atropine Injection 3mg/30ml Minijet	
			Glycopyrronium 1mg in 1ml Oral Solution (Unlicensed) R (Restrict to Specialist and palliative care)	
			Glycopyrronium 1mg Tablets (Unlicensed) R (Restrict to Specialist and Palliative care)	
			Glycopyrronium Injection 600 micrograms/3ml	
			Glycopyrronium Injection 200 micrograms/ml, 1ml. R (Restrict to Paediatrics and Palliative care).	
			Glycopyrronium Injection 400 micrograms/ml R (Restrict to Paediatrics and Palliative care)	
			Glycopyrronium 500 micrograms & Neostigmine 2.5mg/ml Injection	
			Hyoscine Hydrobromide 400mcg/ml and 600mcg/ml Injection	
15.1.4	Sedative and analgesics peri-operative drugs			
15.1.4.1	Benzodiazepines			
			Diazepam 2mg Tablets	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Diazepam 5mg Tablets	
			Diazepam Syrup 2mg/5ml	
			Diazepam Injection 5mg/ml, 2ml	
			Diazepam Injection (Emulsion) 5mg/ml, 2ml	
			Diazepam Rectal Solution 5mg	
			Diazepam Rectal Solution 10mg	
			Lorazepam Tablets 1mg	
			Lorazepam Tablets 2.5mg	
			Lorazepam Injection 4mg/ml, 1ml	
			Midazolam 10mg/ml SF Liquid (Unlicensed) CD	NPSA: Reducing risk of midazolam overdose in adults. Dec 2008
			Midazolam Injection 1mg/1ml , 2ml CD	
			Midazolam Injection 1mg/1ml , 5ml R (Restricted to Air ambulance and Macgregor) CD	
			Midazolam Injection 2mg/ml, 5ml CD	
			Midazolam Injection 5mg/ml, 2ml, 10ml CD	
			Temazepam Tablets 10mg CD	
			Temazepam Tablets Elixir 10mg/5ml CD	
15.1.4.2	Non-opioid Analgesics			
			Ketorolac Trometamol 30mg/ml Injection	
			Parecoxib Injection 40mg	
15.1.4.3	Opioid Analgesics			
			Alfentanil Injection 500 micrograms/ml, 2ml, 10ml CD	
			Alfentanil Injection 5mg/ml CD	
			Fentanyl Injection 50 micrograms/ml, 2ml CD	
			Remifentanil Injection 1mg/3ml CD	
			Remifentanil Injection 2mg/5ml CD	
			Remifentanil Injection 5mg/10ml CD	
			Morphine 100mg in NaCl 0.9% IV INF 100ml CD	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
15.1.5	Neuromuscular Blocking drugs			
			Atracurium Injection 10mg/ml 2.5ml, 5ml, 25ml	
			Mivacurium Injection 2mg/ml, 5ml, 10ml	
			Rocuronium Injection 50mg/5ml	
	Depolarising Neuromuscular blocking drugs			
			Suxamethonium Injection 100mg/2ml	
15.1.6	Drugs for reversal of Neuromuscular Blockade			
			Edrophonium 10mg/ml Injection	
			Neostigmine 2.5mg/ml Injection	
			Sugammadex 100mg/ml Injection 5ml	
15.1.7	Antagonist for Central and Respiratory Depression			
			Doxapram 100mg in 5ml Injection	
			Flumazenil Injection 100 micrograms/ml, 5ml	
			Naloxone Injection 400 micrograms/ml, 1ml	Patient Safety Alert: Risk of distress and death from inappropriate doses of naloxone in patients on long term opioid/opiate treatment. November 2014.
			Naloxone 1mg/ml 2ml PF Syringe	
			Naloxone Neonatal 20mcg in 1ml Injection 2ml R (Restrict to Special - dispense to individual patients)	
15.1.8	Drugs for Malignant Hyperthermia			
			Dantrolene Injection 20mg	
15.2	Local Anaesthesia			

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
				Drugs in section 15.2 should only be administered by or under the direct supervision of personnel experienced in their use, with adequate training in anaesthesia and airways management. It should not be administered parenterally unless adequate resuscitation equipment is available. Warnings or precautions to separate IV from epidural lidocaine
		Bupivacaine		
			Bupivacaine Injection 0.25%, 10ml R (Restrict to specialist).	
			Bupivacaine Injection 0.25% with adrenaline 1 in 200 000 R (Restrict to specialist).	
			Bupivacaine Injection 0.5% with adrenaline 1 in 200 000 R (Restrict to specialist)	
			Bupivacaine Heavy 20mg in 4ml Injection R (Restrict to specialist)	
		Levobupivacaine		
			Levobupivacaine Injection 2.5mg/ml R (Restrict to specialist)	
			Levobupivacaine Injection 5mg/ml R (Restrict to specialist)	
			Levobupivacaine Injection 7.5mg/ml R (Restrict to specialist)	
		Lidocaine		
		glass amps	Lidocaine Injection 0.5%, 10ml R (Restrict to specialist)	
			Lidocaine Injection 1.0%, 5ml, 10ml R (Restrict to specialist)	
			Lidocaine Injection 2.0%, 2ml, 5ml R (Restrict to specialist)	

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
		plastic amps		
			Lidocaine Injection 1.0%, inj 5ml (plastic) R (Restrict to specialist)	
			Lidocaine Hydrochloride 1% Min-I- jet R (Restrict to specialist)	
		Lidocaine 0.5% , 1%, 2% and Adrenaline 1 in 200, 000		
			Lidocaine 1% and Adrenaline 1 in 200, 000 Vial 20ml R (Restrict to specialist)	
			Lidocaine 2% and Adrenaline 1 in 200, 000 Vial 20ml R (Restrict to specialist)	
		Lidocaine 0.5% , 1%, 2% and Adrenaline 1 in 80, 000		
			Lidocaine 2% and Adrenaline 1 in 80, 000 (50 Cartridge pack) 2.2ml R (Restrict to specialist)	
		Lidocaine Topical		
			Lidocaine 5% 700mg Medicated Plaster	
			Lidocaine 5% Phenylephrine 0.5% Nasal Spray	
			Lidocaine 5% Ointment	
			Lidocaine 2% Top Solution R (Restrict to endoscopy)	
			Lidocaine 4% Top Solution 30ml, 50ml (Unlicensed) R (Restrict to endoscopy)	
			Lidocaine 10% Aerosol Spray	
			Instillagel 2% Gel 6ml, 11ml	
			Emla 5% Hospital Pack	
		Prilocaine		

BNF Chapter No	BNF Chapter Drug Group	Drug Group	Formulary Drug	Supporting Documents Guidelines
			Prilocaine 2% (Prilotekal) 20mg/ml Intrathecal Injection R (Restrict to specialist)	
			Ethyl Chloride Spray 100ml	
			Ethyl Chloride Spray 50ml	
<p><u>Discouraged List</u> Topical OTC anaesthetics - rationale for not using - only marginally effective and cause irritation.</p>				